



(86) **Date de dépôt PCT/PCT Filing Date:** 2008/05/23
(87) **Date publication PCT/PCT Publication Date:** 2008/12/24
(45) **Date de délivrance/Issue Date:** 2015/12/01
(85) **Entrée phase nationale/National Entry:** 2009/12/18
(86) **N° demande PCT/PCT Application No.:** EP 2008/004151
(87) **N° publication PCT/PCT Publication No.:** 2008/155000
(30) **Priorité/Priority:** 2007/06/21 (DE10 2007 028 515.0)

(51) **Cl.Int./Int.Cl.** **C07D 471/04** (2006.01),
A61K 31/437 (2006.01), **A61K 31/506** (2006.01),
A61P 25/00 (2006.01), **A61P 31/18** (2006.01)


(72) **Inventeurs/Inventors:**
DORSCH, DIETER, DE;
WUCHRER, MARGARITA, DE;
BURGDORF, LARS THORE, DE;
SIRRENBURG, CHRISTIAN, DE;
ESDAR, CHRISTINA, DE;
MUELLER, THOMAS J. J., DE;
MERKUL, EUGEN, DE

(73) **Propriétaire/Owner:**
MERCK PATENT GMBH, DE

(74) **Agent:** FETHERSTONHAUGH & CO.

(54) **Titre :** DERIVES DE 6-(PYRROLOPYRIDINYL)-PYRIMIDINE-2-YLAMINE ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCER ET DU SIDA

(54) **Title:** 6-(PYRROLOPYRIDINYL) PYRIMIDIN-2-YLAMINE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF CANCER AND AIDS




(57) **Abrégé/Abstract:**

Compounds of the formula (I), (see formula I) in which R¹, R², R³ and R⁴ have the meanings as described in the specification, are inhibitors of cell proliferation/cell vitality and can be employed for the treatment of tumours.

26474-1217

ABSTRACT


Compounds of the formula (I),



- 5 in which R¹, R², R³ and R⁴ have the meanings as described in the specification, are inhibitors of cell proliferation/cell vitality and can be employed for the treatment of tumours.

6 - (PYRROLOPYRIDINYL) PYRIMIDIN-2-YLAMINE DERIVATIVES AND THE USE THEREOF FOR
THE TREATMENT OF CANCER AND AIDS

The invention relates to compounds of the formula I



15

in which

R^1 denotes H, A or $-[C(R^5)_2]_nAr$,

R^2 denotes A, $-[C(R^5)_2]_nAr$, $-[C(R^5)_2]_nHet$,
 $-[C(R^5)_2]_ncycloalkyl$, $-[C(R^5)_2]_nOR^5$, $-[C(R^5)_2]_nN(R^5)_2$ or
 $-[C(R^5)_2]_nCOOR^5$

20

R^3 denotes H, A, Hal, CN, $-[C(R^5)_2]_nAr$, $-[C(R^5)_2]_nHet$ or
 $-[C(R^5)_2]_ncycloalkyl$ or $-[C(R^5)_2]_nN(R^5)_2$,

25

R^4 denotes H, A, $-[C(R^5)_2]_nAr$, $-[C(R^5)_2]_nHet$ or $-[C(R^5)_2]_ncycloalkyl$,

R^5 denotes H or alkyl having 1-6 C atoms,

A denotes unbranched or branched alkyl having 1-10 C atoms,
in which one or two CH_2 groups may be replaced by O or S
atoms and/or by $-CH=CH-$ groups and/or in addition 1-7 H
atoms may be replaced by F,

30

cycloalkyl denotes cyclic alkyl having 3-7 C atoms, which may addition-
ally be substituted by alkyl having 1-6 C atoms,

35

Hal denotes F, Cl, Br or I,

Ar denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR⁵, N(R⁵)₂, NO₂, CN, COOR⁵, CON(R⁵)₂, NR⁵COA, NR⁵SO₂A, COR⁵, SO₂N(R⁵)₂ and/or S(O)_pA,

5 Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, and/or O and/or S atoms which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR⁵, N(R⁵)₂, NO₂, CN, COOR⁵, CON(R⁵)₂, NR⁵COA, NR⁵SO₂A, COR⁵, SO₂NR⁵, S(O)_pA and/or =O (carbonyl oxygen),

10 n denotes 0, 1, 2, 3 or 4,

p denotes 0, 1 or 2,

and pharmaceutically usable derivatives, solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

15

The invention was based on the object of finding novel compounds having valuable properties, in particular those which can be used for the preparation of medicaments.

20

It has been found that the compounds of the formula I and salts and/or solvates thereof have very valuable pharmacological properties while being well tolerated.

25

In particular, they exhibit a cell proliferation/cell vitality-inhibiting action as antagonists or agonists. The compounds according to the invention can therefore be used for the combating and/or treatment of tumours, tumour growth and/or tumour metastases.

30

The antiproliferative action can be tested in a proliferation assay/vitality assay.

Other 4-(pyrrolopyridinyl)pyrimidinyl-2-amine derivatives are described, for example, by P.M. Fresneda et al. in Tetrahedron 57 (2001) 2355-2363.

35

Other 4-(pyrrolopyridinyl)pyrimidinyl-2-amine derivatives are also described by A. Karpov in his dissertation, University of Heidelberg, April 2005.

5 Other aminopyridine derivatives which carry a 2,2,6,6-tetramethylpiperidin-4-yl radical are described in WO 2004/089913 for the treatment of inflammatory and autoimmune diseases.

10 Accordingly, the compounds according to the invention or a pharmaceutically acceptable salt thereof are administered for the treatment of cancer, including solid carcinomas, such as, for example, carcinomas (for example of the lungs, pancreas, thyroid, bladder or colon), myeloid diseases (for example myeloid leukaemia) or adenomas (for example villous colon adenoma).

15 The tumours furthermore include monocytic leukaemia, brain, urogenital, lymphatic system, stomach, laryngeal and lung carcinoma, including lung adenocarcinoma and small-cell lung carcinoma, pancreatic and/or breast carcinoma.

20 The compounds are furthermore suitable for the treatment of immune deficiency induced by HIV-1 (Human Immunodeficiency Virus Type 1).

25 Cancer-like hyperproliferative diseases are to be regarded as brain cancer, lung cancer, squamous epithelial cancer, bladder cancer, stomach cancer, pancreatic cancer, liver cancer, renal cancer, colorectal cancer, breast cancer, head cancer, neck cancer, oesophageal cancer, gynaecological cancer, thyroid cancer, lymphomas, chronic leukaemia and acute leukaemia. In particular, cancer-like cell growth is a disease which represents a target of the present invention. The present invention therefore relates to compounds according to the invention as medicaments and/or medication active ingredients in the treatment and/or prophylaxis of the said diseases and to the use of compounds according to the invention for the preparation of a pharmaceutical for the treatment and/or prophylaxis of the

30

35

said diseases and to a process for the treatment of the said diseases comprising the administration of one or more compounds according to the invention to a patient in need of such an administration.

5 It can be shown that the compounds according to the invention have an antiproliferative action. The compounds according to the invention are administered to a patient having a hyperproliferative disease, for example to inhibit tumour growth, to reduce inflammation associated with a lympho-
10 proliferative disease, to inhibit transplant rejection or neurological damage due to tissue repair, etc. The present compounds are suitable for prophylactic or therapeutic purposes. As used herein, the term "treatment" is used to refer to both the prevention of diseases and the treatment of pre-
15 existing conditions. The prevention of proliferation/vitality is achieved by administration of the compounds according to the invention prior to the development of overt disease, for example for preventing tumour growth. Alternatively, the compounds are used for the treatment of ongoing dis-
20 eases by stabilising or improving the clinical symptoms of the patient.

The host or patient can belong to any mammalian species, for example a primate species, particularly humans; rodents, including mice, rats and hamsters; rabbits; horses, cows, dogs, cats, etc. Animal models are of
25 interest for experimental investigations, providing a model for treatment of a human disease.

The susceptibility of a particular cell to treatment with the compounds
30 according to the invention can be determined by in vitro testing. Typically, a culture of the cell is incubated with a compound according to the invention at various concentrations for a period of time which is sufficient to allow the active agents to induce cell death or to inhibit cell proliferation, cell vitality or migration, usually between about one hour and one week. In
35 vitro testing can be carried out using cultivated cells from a biopsy sample. The amount of cells remaining after the treatment are then determined.

5 The dose varies depending on the specific compound used, the specific disease, the patient status, etc. A therapeutic dose is typically sufficient considerably to reduce the undesired cell population in the target tissue, while the viability of the patient is maintained. The treatment is generally continued until a considerable reduction has occurred, for example an at least about 50% reduction in the cell burden, and may be continued until essentially no more undesired cells are detected in the body.

10 There are many diseases associated with deregulation of cell proliferation and cell death (apoptosis). The conditions of interest include, but are not limited to, the following. The compounds according to the invention are suitable for the treatment of various conditions where there is proliferation and/or migration of smooth muscle cells and/or inflammatory cells into the
15 intimal layer of a vessel, resulting in restricted blood flow through that vessel, for example in the case of neointimal occlusive lesions. Occlusive graft vascular diseases of interest include atherosclerosis, coronary vascular disease after grafting, vein graft stenosis, perianastomatic prosthetic
20 restenosis, restenosis after angioplasty or stent placement, and the like.

The compounds of the formula I, also act as regulators, modulators or inhibitors of protein kinases, in particular of the serine/threonine kinase
25 type, which include, inter alia, phosphoinositide-dependent kinase (PDK). The compounds according to the invention exhibit a certain action in the inhibition of serine/threonine kinase PDK1.

30 PDK1 phosphorylates and activates a sub-group of the AGC protein kinase family, comprising PKB, SGK, S6K and PKC isoforms. These kinases are involved in the PI3K signal transduction pathway and control basic cellular functions, such as survival, growth and differentiation. PDK1 is thus an important regulator of diverse metabolic, proliferative and life-
35 sustaining effects.

5 Diseases caused by protein kinases are characterised by anomalous activity or hyperactivity of such protein kinases. Anomalous activity relates either to: (1) the expression in cells which do not usually express these protein kinases; (2) increased kinase expression which results in undesired cell proliferation, such as cancer; (3) increased kinase activity which results in undesired cell proliferation, such as cancer, and/or in hyperactiv-
10 ity of the corresponding protein kinases. Hyperactivity relates either to amplification of the gene which encodes a certain protein kinase or the generation of an activity level which can be correlated with a cell proliferation disease (i.e. the severity of one or more symptoms of the cell proliferation disease increases with increasing kinase level) the bioavailability of a protein kinase can also be influenced by the presence or absence of a set of
15 binding proteins of this kinase.

The most important types of cancer that can be treated using a compound according to the invention include colorectal cancer, small-cell lung cancer, non-small-cell lung cancer, multiple myeloma as well as renal cell carcinoma and endometrium carcinoma, particularly also types of cancer in
20 which PTEN is mutated, inter alia breast cancer, prostate cancer and glioblastoma.

25 In addition, the compounds according to the invention can be used to achieve additive or synergistic effects in certain existing cancer chemotherapies and radiotherapies and/or to restore the efficacy of certain existing cancer chemotherapies and radiotherapies.

30 The invention also relates to the optically active forms (stereoisomers), salts, the enantiomers, the racemates, the diastereomers and the hydrates and solvates of these compounds. The term solvates of the compounds is taken to mean adductions of inert solvent molecules onto the compounds
35 which form owing to their mutual attractive force. Solvates are, for example, mono- or dihydrates or alkoxides.

The term pharmaceutically usable derivatives is taken to mean, for example, the salts of the compounds according to the invention and also so-called prodrug compounds.

5 The term prodrug derivatives is taken to mean compounds of the formula I which have been modified by means of, for example, alkyl or acyl groups, sugars or oligopeptides and which are rapidly cleaved in the organism to form the effective compounds according to the invention.

10 These also include biodegradable polymer derivatives of the compounds according to the invention, as described, for example, in Int. J. Pharm. 115, 61-67 (1995).

15 The expression "effective amount" denotes the amount of a medicament or of a pharmaceutical active ingredient which causes in a tissue, system, animal or human a biological or medical response which is sought or desired, for example, by a researcher or physician.

20 In addition, the expression "therapeutically effective amount" denotes an amount which, compared with a corresponding subject who has not received this amount, has the following consequence:

improved treatment, healing, prevention or elimination of a disease, syndrome, condition, complaint, disorder or side effects or also the reduction in the advance of a disease, condition or disorder.

25 The expression "therapeutically effective amount" also encompasses the amounts which are effective for increasing normal physiological function.

30 The invention also relates to the use of mixtures of the compounds of the formula I, for example mixtures of two diastereomers, for example in the ratio 1:1, 1:2, 1:3, 1:4, 1:5, 1:10, 1:100 or 1:1000.

These are particularly preferably mixtures of stereoisomeric compounds.


35 The invention relates to the compounds of the formula I and salts thereof and to a process for the preparation of compounds of the formula I accord-

ing to Claims 1-13 and pharmaceutically usable derivatives, salts, solvates, tautomers and stereoisomers thereof, characterised in that

a) a compound of the formula II

5

10



15

in which R^1 denotes an indole-protecting group,
 R^2 , R^3 and R^4 have the meanings indicated in Claim 1,

is reacted with guanidine,

20

and the indole-protecting group is simultaneously or subsequently cleaved off,

or

25

b) a radical R^2 in a compound of the formula I is converted into another R^2

by

30

- i) cleaving off an amino-protecting group,
- ii) cleaving an imide to give an amine,
- iii) carrying out an alkylation,

and/or a base or acid of the formula I is converted into one of its salts.

35

Above and below, the radicals R^1 , R^2 , R^3 and R^4 have the meanings indicated for the formula I, unless expressly indicated otherwise.

5 A denotes alkyl, is unbranched (linear) or branched, and has 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms. A preferably denotes methyl, furthermore ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, furthermore also pentyl, 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1,1-, 1,2-, 1,3-, 2,2-, 2,3- or 10 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, 1,1,2- or 1,2,2-trimethylpropyl, further preferably, for example, trifluoromethyl.

A very particularly preferably denotes alkyl having 1, 2, 3, 4, 5 or 6 C 15 atoms, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, trifluoromethyl, pentafluoroethyl or 1,1,1-trifluoroethyl.

One or two CH_2 groups in A may also be replaced by O or S atoms and/or 20 by $-\text{CH}=\text{CH}-$ groups. A thus also denotes, for example, 2-methoxyethyl.

Cycloalkyl preferably denotes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.

25 Ar denotes, for example, phenyl, o-, m- or p-tolyl, o-, m- or p-ethylphenyl, o-, m- or p-propylphenyl, o-, m- or p-isopropylphenyl, o-, m- or p-tert-butylphenyl, o-, m- or p-trifluoromethylphenyl, o-, m- or p-fluorophenyl, o-, m- or p-bromophenyl, o-, m- or p-chlorophenyl, o-, m- or p-hydroxyphenyl, o-, m- or p-methoxyphenyl, o-, m- or p-methylsulfonylphenyl, o-, m- or p-nitrophenyl, o-, m- or p-aminophenyl, o-, m- or p-methylaminophenyl, o-, m- or p-dimethylaminophenyl, o-, m- or p-aminosulfonylphenyl, o-, m- or p-methylaminosulfonylphenyl, o-, m- or p-aminocarbonylphenyl, o-, m- or 35 p-carboxyphenyl, o-, m- or p-methoxycarbonylphenyl, o-, m- or p-ethoxycarbonylphenyl, o-, m- or p-acetylphenyl, o-, m- or p-formylphenyl, o-, m- or p-cyanophenyl, further preferably 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-di-

fluorophenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dichlorophenyl, 2,3-, 2,4-,
2,5-, 2,6-, 3,4- or 3,5-dibromophenyl, 2,3,4-, 2,3,5-, 2,3,6-, 2,4,6- or 3,4,5-
trichlorophenyl, p-iodophenyl, 4-fluoro-3-chlorophenyl, 2-fluoro-4-bromo-
phenyl, 2,5-difluoro-4-bromophenyl or 2,5-dimethyl-4-chlorophenyl.

Ar particularly preferably denotes phenyl which is unsubstituted or mono-,
di- or trisubstituted by A, NO₂, N(R⁵)₂, CN and/or COOR⁵.

Irrespective of further substitutions, Het denotes, for example, 2- or 3-furyl,
2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2, 4- or 5-imidazolyl, 1-, 3-, 4- or
5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl,
3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, further-
more preferably 1,2,3-triazol-1-, -4- or -5-yl, 1,2,4-triazol-1-, -3- or 5-yl, 1-
or 5-tetrazolyl, 1,2,3-oxadiazol-4- or -5-yl, 1,2,4-oxadiazol-3- or -5-yl, 1,3,4-
thiadiazol-2- or -5-yl, 1,2,4-thiadiazol-3- or -5-yl, 1,2,3-thiadiazol-4- or -5-yl,
3- or 4-pyridazinyl, pyrazinyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 4- or 5-iso-
indolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indazolyl, 1-,
3-, 4-, 5-, 6- or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5-,
6- or 7- benzisoxazolyl, 2-, 4-, 5-, 6- or 7-benzothiazolyl, 2-, 4-, 5-, 6- or
7-benzisothiazolyl, 4-, 5-, 6- or 7-benz-2,1,3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-,
7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl, 3-, 4-, 5-, 6-, 7- or 8-
cinnolyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, 5- or 6-quinoxalyl, 2-, 3-, 5-,
6-, 7- or 8-2H-benzo-1,4-oxazinyl, further preferably 1,3-benzodioxol-5-yl,
1,4-benzodioxan-6-yl, 2,1,3-benzothiadiazol-4- or -5-yl or 2,1,3-benzoxa-
diazol-5-yl.

The heterocyclic radicals may also be partially or fully hydrogenated.

Unsubstituted Het can thus also denote, for example, 2,3-dihydro-2-, -3-,
-4- or -5-furyl, 2,5-dihydro-2-, -3-, -4- or 5-furyl, tetrahydro-2- or -3-furyl,
1,3-dioxolan-4-yl, tetrahydro-2- or -3-thienyl, 2,3-dihydro-1-, -2-, -3-, -4- or
-5-pyrrolyl, 2,5-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 1-, 2- or 3-pyrrolidinyl,
tetrahydro-1-, -2- or -4-imidazolyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyra-
zolyl, tetrahydro-1-, -3- or -4-pyrazolyl, 1,4-dihydro-1-, -2-, -3- or -4-pyridyl,

1,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5- or -6-pyridyl, 1-, 2-, 3- or 4-piperidiny, 2-, 3- or 4-morpholinyl, tetrahydro-2-, -3- or -4-pyranyl, 1,4-dioxanyl, 1,3-dioxan-2-, -4- or -5-yl, hexahydro-1-, -3- or -4-pyridazinyl, hexahydro-1-,
5 -2-, -4- or -5-pyrimidinyl, 1-, 2- or 3-piperazinyl, 1,2,3,4-tetrahydro-1-, -2-,
-3-, -4-, -5-, -6-, -7- or -8-quinolyl, 1,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5-, -6-,
-7- or -8-isoquinolyl, 2-, 3-, 5-, 6-, 7- or 8- 3,4-dihydro-2H-benzo-1,4-oxaz-
inyl, further preferably 2,3-methylenedioxyphenyl, 3,4-methylenedioxy-
phenyl, 2,3-ethylenedioxyphenyl, 3,4-ethylenedioxyphenyl, 3,4-(difluoro-
10 methylenedioxy)phenyl, 2,3-dihydrobenzofuran-5- or 6-yl, 2,3-(2-oxo-
methylenedioxy)phenyl or also 3,4-dihydro-2H-1,5-benzodioxepin-6- or -7-
yl, furthermore preferably 2,3-dihydrobenzofuranyl or 2,3-dihydro-2-oxo-
furanyl.

15 Het furthermore preferably denotes a mono- or bicyclic saturated, unsatu-
rated or aromatic heterocycle having 1 to 3 N and/or O atoms which is un-
substituted or mono- or di- or trisubstituted by A, OH, OA, Hal, $\text{CON}(\text{R}^5)_2$,
20 $\text{N}(\text{R}^5)_2$ and/or $=\text{O}$ (carbonyl oxygen);
furthermore particularly preferably dihydropyrrolyl, pyrrolidinyl, tetrahydro-
imidazolyl, dihydropyrazolyl, tetrahydropyrazolyl, dihydropyridyl, tetrahydro-
pyridyl, piperidiny, morpholinyl, hexahydropyridazinyl, hexahydro-pyrimid-
inyl, piperazinyl, 1,2,3,4-tetrahydroquinolyl, 1,2,3,4-tetrahydro-isoquinolyl,
25 3,4-dihydrobenzo-1,4-oxazinyl, 2,3-dihydroisoindolyl, 2,3-dihydroindolyl,
oxazolidinyl, isoxazolidinyl, oxadiazolidinyl, thiazolidinyl, furyl, thienyl, pyr-
rolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridyl, pyrimid-
inyl, triazolyl, tetrazolyl, thiadiazole, pyridazinyl, pyrazinyl, indolyl, isoindo-
30 lyl, benzimidazolyl, indazolyl, quinolyl or 1,3-benzodioxolyl, each of which
is unsubstituted or mono-, di or trisubstituted by A, OH, OA, Hal,
 $\text{CON}(\text{R}^5)_2$, $\text{N}(\text{R}^5)_2$ and/or $=\text{O}$.

35 Het very particularly preferably denotes dihydropyrrolyl, pyrrolidinyl, tetra-
hydroimidazolyl, dihydropyrazolyl, tetrahydropyrazolyl, dihydropyridyl,
tetrahydropyridyl, piperidiny, morpholinyl, hexahydropyridazinyl, hexa-

- 5 hydropyrimidinyl, piperazinyl, 1,2,3,4-tetrahydroquinolyl, 1,2,3,4-tetrahydroisoquinolyl, 3,4-dihydrobenzo-1,4-oxazinyl, 2,3-dihydroisoindolyl or 2,3-dihydroindolyl, pyrazolyl, pyridyl, furyl or isooxazole, each of which is unsubstituted or mono- or di or trisubstituted by A, $\text{CON}(\text{R}^5)_2$, $\text{N}(\text{R}^5)_2$ or F and/or =O.
- 10 R^1 preferably denotes H or $-\text{[C(R}^5\text{)}_2\text{]}_n\text{Ar}$.
 R^2 denotes A, $-\text{[C(R}^5\text{)}_2\text{]}_n\text{Ar}$, $-\text{[C(R}^5\text{)}_2\text{]}_n\text{Het}$, $-\text{[C(R}^5\text{)}_2\text{]}_n\text{cycloalkyl}$, $-\text{[C(R}^5\text{)}_2\text{]}_n\text{OR}^5$, $-\text{[C(R}^5\text{)}_2\text{]}_n\text{N(R}^5\text{)}_2$ or $-\text{[C(R}^5\text{)}_2\text{]}_n\text{COOR}^5$
- 15 preferably methyl, ethyl, propyl, butyl, benzyl, phenyl, o-, m- or p-tolyl, o-, m- or p-ethylphenyl, o-, m- or p-propylphenyl, o-, m- or p-isopropylphenyl, o-, m- or p-butylphenyl, o-, m- or p-tert-butylphenyl, o-, m- or p-trifluoromethylphenyl, 4-propylcyclohexyl, methoxymethyl, hydroxymethyl, 1,3-dioxoisoindol-2-ylmethyl, 1,3-dioxoisoindol-2-ylethyl, 1,3-dioxoisoindol-2-ylpropyl, 1,3-dioxoisoindol-2-ylbutyl, aminomethyl, aminoethyl, amino-
- 20 propyl, aminobutyl, dimethylaminomethyl, dimethylaminopropyl, pyrrolidin-1-ylpropyl, piperidin-4-ylmethyl, 1-methylpiperidin-4-ylmethyl, piperidin-4-ylpropyl, 1-methylpiperidin-4-ylmethyl, pyrrolidin-2-ylethyl or 3-morpholin-4-ylpropyl, 3-piperazin-1-ylpropyl, aminophenyl, 3-carboxypropyl, nitrophenyl, 4-hydroxybutyl, 3-hydroxypropyl, hydroxymethyl, 2-carboxyethyl or 3-(4-methylpiperazin-1-yl)propyl.
- 25
- 30 R^3 preferably denotes H, Br, Cl, CN, Ar or Het
 R^4 preferably denotes H or A
 R^5 preferably denotes H or A
- 35 Hal preferably denotes F, Cl or Br, but also I, particularly preferably F or Cl.

Throughout the invention, all radicals which occur more than once may be identical or different, i.e. are independent of one another.

The compounds of the formula I may have one or more chiral centres and can therefore occur in various stereoisomeric forms. The formula I encompasses all these forms.

Accordingly, the invention relates, in particular, to the compounds of the formula I in which at least one of the said radicals has one of the preferred meanings indicated above. Some preferred groups of compounds may be expressed by the following sub-formulae Ia to II, which conform to the formula I and in which the radicals not designated in greater detail have the meaning indicated for the formula I, but in which

in Ia R^1 denotes H or $-[C(R^5)_2]_nAr$;

in Ib R^2 denotes methyl, ethyl, propyl, butyl, benzyl, phenyl, o-, m- or p-tolyl, o-, m- or p-ethylphenyl, o-, m- or p-propylphenyl, o-, m- or p-isopropylphenyl, o-, m- or p-butylphenyl, o-, m- or p-tert-butylphenyl, o-, m- or p-trifluoromethylphenyl, 4-propylcyclohexyl, methoxymethyl, hydroxymethyl, 1,3-dioxoisindol-2-ylmethyl, 1,3-dioxoisindol-2-ylethyl, 1,3-dioxoisindol-2-ylpropyl, 1,3-dioxoisindol-2-ylbutyl, aminomethyl, aminoethyl, aminopropyl, aminobutyl, dimethylaminomethyl, dimethylaminopropyl, pyrrolidin-1-ylpropyl, piperidin-4-ylmethyl, 1-methylpiperidin-4-ylmethyl, piperidin-4-ylpropyl, 1-methylpiperidin-4-ylethyl, pyrrolidin-2-ylethyl or 3-morpholin-4-ylpropyl, 3-piperazin-1-ylpropyl, aminophenyl, 3-carboxypropyl, nitrophenyl, 4-hydroxybutyl, 3-hydroxypropyl, hydroxymethyl, 2-carboxyethyl or 3-(4-methylpiperazin-1-yl)propyl;

	in Ic	R^3	denotes H, Br, Cl, CN, Ar or Het;
	in Id	R^4	denotes H or A;
5	in Ie	R^5	denotes H or A;
10	in If	A	denotes unbranched or branched alkyl having 1-8 C atoms, in which one or two CH_2 group may be replaced by oxygen and/or in addition 1-7 H atoms may be replaced by F;
15	in Ig	A	denotes unbranched or branched alkyl having 1-6 C atoms, in which one or two CH_2 group may be replaced by oxygen and/or 1-7 H atoms may be replaced by F;
20	in Ih	Ar	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A, NO_2 , $N(R^5)_2$, CN and/or $COOR^5$;
25	in Ii	Het	denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 3 N and/or O atoms which is unsubstituted or mono- or di- or trisubstituted by A, OH, OA, Hal, $CON(R^5)_2$, $N(R^5)_2$ and/or =O (carbonyl oxygen);
30	in Ij	Het	denotes dihydropyrrolyl, pyrrolidinyl, tetrahydroimidazolyl, dihydropyrazolyl, tetrahydropyrazolyl, dihydropyridyl, tetrahydropyridyl, piperidinyl, morpholinyl, hexahydropyridazinyl, hexahydropyrimidinyl, piperazinyl, 1,2,3,4-tetrahydroquinolyl, 1,2,3,4-tetrahydroisoquinolyl, 3,4-dihydrobenzo-1,4-oxazinyl, 2,3-dihydroisoindolyl, 2,3-dihydroindolyl, oxazolidinyl, isoxazolidinyl, oxadiazolidinyl, thiazolidinyl, furyl, thienyl, pyrrolyl, imida-
35			

5				zolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl, thiadiazole, pyridazinyl, pyrazinyl, indolyl, isoindolyl, benzimidazolyl, indazolyl, quinolyl or 1,3-benzodioxolyl, each of which is unsubstituted or mono- or di- or trisubstituted by A, OH, OA, Hal, $\text{CON}(\text{R}^5)_2$, $\text{N}(\text{R}^5)_2$ and/or $=\text{O}$;
10		in Ik	Het	denotes dihydropyrrolyl, pyrrolidinyl, tetrahydroimidazolyl, dihydropyrazolyl, tetrahydropyrazolyl, dihydropyridyl, tetrahydropyridyl, piperidinyl, morpholinyl, hexahydropyridazinyl, hexahydropyrimidinyl, piperazinyl, 1,2,3,4-tetrahydroquinolyl, 1,2,3,4-tetrahydroisoquinolyl, 3,4-dihydrobenzo-1,4-oxazinyl, 2,3-dihydroisoindolyl or 2,3-dihydroindolyl, pyrazolyl, pyridyl, furyl or isoxazole, each of which is unsubstituted or mono- or di-, or trisubstituted by A, $\text{CON}(\text{R}^5)_2$, $\text{N}(\text{R}^5)_2$ or F and/or $=\text{O}$;
15				
20		in II	R^1	denotes H or $-\text{[C}(\text{R}^5)_2\text{]}_n\text{Ar}$,
			R^2	denotes A, $-\text{[C}(\text{R}^5)_2\text{]}_n\text{Ar}$, $-\text{[C}(\text{R}^5)_2\text{]}_n\text{Het}$, $-\text{[C}(\text{R}^5)_2\text{]}_n\text{cycloalkyl}$, $-\text{[C}(\text{R}^5)_2\text{]}_n\text{OR}^5$, $-\text{[C}(\text{R}^5)_2\text{]}_n\text{N}(\text{R}^5)_2$ or $-\text{[C}(\text{R}^5)_2\text{]}_n\text{COOR}^5$
25				$-\text{[C}(\text{R}^5)_2\text{]}_n\text{COOR}^5$
			R^3	denotes H, Br, Cl, CN, Ar or Het
			R^4	denotes H or A,
			R^5	denotes H or A,
30			A	denotes unbranched or branched alkyl having 1-6 C atoms, in which one or two CH_2 groups may be replaced by oxygen and/or 1-7 H atoms may be replaced by F,
			Ar	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A, NO_2 , $\text{N}(\text{R}^5)_2$, CN and/or COOR^5 ,
35			Het	denotes dihydropyrrolyl, pyrrolidinyl, tetrahydroimidazolyl, dihydropyrazolyl, tetrahydropyrazolyl, dihydro-

pyridyl, tetrahydropyridyl, piperidinyl, morpholinyl, hexahydropyridazinyl, hexahydropyrimidinyl, piperazinyl, 1,2,3,4-tetrahydroquinolyl, 1,2,3,4-tetrahydroisoquinolyl, 3,4-dihydrobenzo-1,4-oxazinyl, 2,3-dihydroisoindolyl or 2,3-dihydroindolyl, pyrazolyl, pyridyl, furyl or isoxazole, each of which is unsubstituted or mono- or di- or trisubstituted by A, $\text{CON}(\text{R}^5)_2$, $\text{N}(\text{R}^5)_2$ or F and/or =O

n denotes 0, 1, 2, 3 or 4;

and pharmaceutically usable derivatives, salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

The compounds of the formula I and also the starting materials for their preparation are, in addition, prepared by methods known per se, as described in the literature (for example in the standard works, such as Houben-Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Georg-Thieme-Verlag, Stuttgart), to be precise under reaction conditions which are known and suitable for the said reactions. Use can also be made here of variants known per se which are not mentioned here in greater detail.

Compounds of the formula I can preferably be obtained by reacting compounds of the formula II and with a guanidine salt, such as, for example, guanidinium carbonate.

The compounds of the formula II are generally known. If they are novel, however, they can be prepared by methods known per se.

The reaction is carried out in an inert solvent and is generally carried out in the presence of an acid-binding agent, preferably an organic base, such as DIPEA, triethylamine, dimethylaniline, pyridine or quinoline.

The addition of an alkali or alkaline-earth metal hydroxide, carbonate or bicarbonate or another salt of a weak acid of the alkali or alkaline-earth

metals, preferably of potassium, sodium, calcium or caesium, may also be favourable.

5 Depending on the conditions used, the reaction time is between a few minutes and 14 days, the reaction temperature is between about -15° and 150° , normally between 40° and 130° , particularly preferably between 60° and 110°C .

10 Suitable inert solvents are, for example, hydrocarbons, such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons, such as trichloroethylene, 1,2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane; alcohols, such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; ethers, such as diethyl ether,
15 diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers, such as ethylene glycol monomethyl or monoethyl ether, ethylene glycol dimethyl ether (diglyme); ketones, such as acetone or butanone; amides, such as acetamide, dimethylacetamide or dimethylformamide (DMF); nitriles, such
20 as acetonitrile; sulfoxides, such as dimethyl sulfoxide (DMSO); carbon disulfide; carboxylic acids, such as formic acid or acetic acid; nitro compounds, such as nitromethane or nitrobenzene; esters, such as ethyl acetate, or mixtures of the said solvents.

25 Particular preference is given to glycol ethers, such as ethylene glycol monomethyl ether, THF, dichloromethane and/or DMF.

30 Preferred indole-protecting groups are, for example, sulfonyl-protecting groups, such as tosyl or mesyl, furthermore protecting groups such as, for example, BOC.

The cleavage of an ether is carried out by methods as are known to the person skilled in the art.

35 A standard method of ether cleavage, for example of a methyl ether, is the use of boron tribromide.

Hydrogenolytically removable groups, for example the cleavage of a benzyl ether, can be cleaved off, for example, by treatment with hydrogen in the presence of a catalyst (for example a noble-metal catalyst, such as palladium, advantageously on a support, such as carbon). Suitable solvents here are those indicated above, in particular, for example, alcohols, such as methanol or ethanol, or amides, such as DMF. The hydrogenolysis is generally carried out at temperatures between about 0 and 100° and pressures between about 1 and 200 bar, preferably at 20-30° and 1-10 bar.

5
10

Esters can be saponified, for example, using acetic acid or using NaOH or KOH in water, water/THF or water/dioxane, at temperatures between 0 and 100°.

15

Alkylations on the nitrogen are carried out under standard conditions, as are known to the person skilled in the art.

20

The compounds of the formulae I can furthermore be obtained by liberating them from their functional derivatives by solvolysis, in particular hydrolysis, or by hydrogenolysis.

25

Preferred starting materials for the solvolysis or hydrogenolysis are those which contain corresponding protected amino and/or hydroxyl groups instead of one or more free amino and/or hydroxyl groups, preferably those which carry an amino-protecting group instead of an H atom bonded to an N atom, for example those which conform to the formula I, but contain an NHR' group (in which R' denotes an amino-protecting group, for example BOC or CBZ) instead of an NH₂ group.

30

35

Preference is furthermore given to starting materials which carry a hydroxyl-protecting group instead of the H atom of a hydroxyl group, for example those which conform to the formula I, but contain an R''O-phenyl

group (in which R" denotes a hydroxyl-protecting group) instead of a hydroxyphenyl group.

5 It is also possible for a plurality of – identical or different – protected amino and/or hydroxyl groups to be present in the molecule of the starting material. If the protecting groups present are different from one another, they can in many cases be cleaved off selectively.

10 The expression "amino-protecting group" is known in general terms and relates to groups which are suitable for protecting (blocking) an amino group against chemical reactions, but are easy to remove after the desired chemical reaction has been carried out elsewhere in the molecule. Typical
15 of such groups are, in particular, unsubstituted or substituted acyl, aryl, aralkoxymethyl or aralkyl groups. Since the amino-protecting groups are removed after the desired reaction (or reaction sequence), their type and size is furthermore not crucial; however, preference is given to those having 1-20, in particular 1-8, C atoms. The expression "acyl group" is to be
20 understood in the broadest sense in connection with the present process. It includes acyl groups derived from aliphatic, araliphatic, aromatic or heterocyclic carboxylic acids or sulfonic acids, and, in particular, alkoxy-carbonyl, aryloxy-carbonyl and especially aralkoxycarbonyl groups. Examples
25 of such acyl groups are alkanoyl, such as acetyl, propionyl, butyryl; aralkanoyl, such as phenylacetyl; aroyl, such as benzoyl, tolyl; aryloxy-alkanoyl, such as POA; alkoxy-carbonyl, such as methoxycarbonyl, ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, BOC, 2-iodoethoxycarbonyl; aralkoxycarbonyl, such as CBZ ("carbobenzoxyl"), 4-methoxybenzyloxy-carbonyl, FMOC; arylsulfonyl, such as Mtr, Pbf, Pmc. Preferred amino-protecting groups are BOC and Mtr, furthermore CBZ, Fmoc, benzyl and
30 acetyl.

35 The expression "hydroxyl-protecting group" is likewise known in general terms and relates to groups which are suitable for protecting a hydroxyl

group against chemical reactions, but are easy to remove after the desired chemical reaction has been carried out elsewhere in the molecule. Typical of such groups are the above-mentioned unsubstituted or substituted aryl, aralkyl or acyl groups, furthermore also alkyl groups. The nature and size of the hydroxyl-protecting groups is not crucial since they are removed again after the desired chemical reaction or reaction sequence; preference is given to groups having 1-20, in particular 1-10, C atoms. Examples of hydroxyl-protecting groups are, inter alia, tert-butoxycarbonyl, benzyl, p-nitrobenzoyl, p-toluenesulfonyl, tert-butyl and acetyl, where benzyl and tert-butyl are particularly preferred. The COOH groups in aspartic acid and glutamic acid are preferably protected in the form of their tert-butyl esters (for example Asp(OBut)).

The compounds of the formula I are liberated from their functional derivatives – depending on the protecting group used – for example using strong acids, advantageously using TFA or perchloric acid, but also using other strong inorganic acids, such as hydrochloric acid or sulfuric acid, strong organic carboxylic acids, such as trichloroacetic acid, or sulfonic acids, such as benzene- or p-toluenesulfonic acid. The presence of an additional inert solvent is possible, but is not always necessary. Suitable inert solvents are preferably organic, for example carboxylic acids, such as acetic acid, ethers, such as tetrahydrofuran or dioxane, amides, such as DMF, halogenated hydrocarbons, such as dichloromethane, furthermore also alcohols, such as methanol, ethanol or isopropanol, and water. Mixtures of the above-mentioned solvents are furthermore suitable. TFA is preferably used in excess without addition of a further solvent, perchloric acid is preferably used in the form of a mixture of acetic acid and 70% perchloric acid in the ratio 9:1. The reaction temperatures for the cleavage are advantageously between about 0 and about 50°, preferably between 15 and 30° (room temperature).

5 The BOC, OBut, Pbf, Pmc and Mtr groups can, for example, preferably be cleaved off using TFA in dichloromethane or using approximately 3 to 5 N HCl in dioxane at 15-30°, the FMOC group can be cleaved off using an approximately 5 to 50% solution of dimethylamine, diethylamine or piperidine in DMF at 15-30°.

10 Hydrogenolytically removable protecting groups (for example CBZ or benzyl) can be cleaved off, for example, by treatment with hydrogen in the presence of a catalyst (for example a noble-metal catalyst, such as palladium, advantageously on a support, such as carbon). Suitable solvents here are those indicated above, in particular, for example, alcohols, such as methanol or ethanol, or amides, such as DMF. The hydrogenolysis is
15 generally carried out at temperatures between about 0 and 100° and pressures between about 1 and 200 bar, preferably at 20-30° and 1-10 bar. Hydrogenolysis of the CBZ group succeeds well, for example, on 5 to 10% Pd/C in methanol or using ammonium formate (instead of hydrogen) on Pd/C in methanol/DMF at 20-30°.
20

Pharmaceutical salts and other forms

The said compounds according to the invention can be used in their final non-salt form. On the other hand, the present invention also encompasses
25 the use of these compounds in the form of their pharmaceutically acceptable salts, which can be derived from various organic and inorganic acids and bases by procedures known in the art. Pharmaceutically acceptable salt forms of the compounds of the formula I are for the most part prepared by conventional methods. If the compound of the formula I contains a carboxyl group, one of its suitable salts can be formed by reacting the compound with a suitable base to give the corresponding base-addition salt.
30 Such bases are, for example, alkali metal hydroxides, including potassium hydroxide, sodium hydroxide and lithium hydroxide; alkaline-earth metal hydroxides, such as barium hydroxide and calcium hydroxide; alkali metal alkoxides, for example potassium ethoxide and sodium propoxide; and
35

various organic bases, such as piperidine, diethanolamine and N-methyl-
glutamine. The aluminium salts of the compounds of the formula I are like-
wise included. In the case of certain compounds of the formula I, acid-
addition salts can be formed by treating these compounds with pharma-
5 ceutically acceptable organic and inorganic acids, for example hydrogen
halides, such as hydrogen chloride, hydrogen bromide or hydrogen iodide,
other mineral acids and corresponding salts thereof, such as sulfate,
nitrate or phosphate and the like, and alkyl- and monoarylsulfonates, such
10 as ethanesulfonate, toluenesulfonate and benzenesulfonate, and other
organic acids and corresponding salts thereof, such as acetate, trifluoro-
acetate, tartrate, maleate, succinate, citrate, benzoate, salicylate, ascor-
bate and the like. Accordingly, pharmaceutically acceptable acid-addition
15 salts of the compounds of the formula I include the following: acetate, adi-
pate, alginate, arginate, aspartate, benzoate, benzenesulfonate (besylate),
bisulfate, bisulfite, bromide, butyrate, camphorate, camphorsulfonate,
caprylate, chloride, chlorobenzoate, citrate, cyclopentanepropionate, diglu-
conate, dihydrogenphosphate, dinitrobenzoate, dodecylsulfate, ethane-
20 sulfonate, fumarate, galacterate (from mucic acid), galacturonate, gluco-
heptanoate, gluconate, glutamate, glycerophosphate, hemisuccinate,
hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydro-
bromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isethionate, iso-
25 butyrate, lactate, lactobionate, malate, maleate, malonate, mandelate,
metaphosphate, methanesulfonate, methylbenzoate, monohydrogenphos-
phate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, oleate, palmo-
ate, pectinate, persulfate, phenylacetate, 3-phenylpropionate, phosphate,
30 phosphonate, phthalate, but this does not represent a restriction.

Furthermore, the base salts of the compounds according to the invention
include aluminium, ammonium, calcium, copper, iron(III), iron(II), lithium,
35 magnesium, manganese(III), manganese(II), potassium, sodium and zinc
salts, but this is not intended to represent a restriction. Of the above-men-
tioned salts, preference is given to ammonium; the alkali metal salts

5 sodium and potassium, and the alkaline-earth metal salts calcium and magnesium. Salts of the compounds of the formula I which are derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary and tertiary amines, substituted amines, also including naturally occurring substituted amines, cyclic amines, and basic ion exchanger resins, for example arginine, betaine, caffeine, chlorprocaine, choline, N,N'-dibenzylethylenediamine (benzathine), dicyclohexylamine, diethanolamine, diethylamine, 2-diethylaminoethanol, 2-dimethylamino-ethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lidocaine, lysine, meglumine, N-methyl-D-glucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethanolamine, triethylamine, trimethylamine, tripropylamine and tris-(hydroxymethyl)methylamine (tromethamine), but this is not intended to represent a restriction.

20 Compounds of the present invention which contain basic nitrogen-containing groups can be quaternised using agents such as (C₁-C₄)alkyl halides, for example methyl, ethyl, isopropyl and tert-butyl chloride, bromide and iodide; di(C₁-C₄)alkyl sulfates, for example dimethyl, diethyl and diamyl sulfate; (C₁₀-C₁₈)alkyl halides, for example decyl, dodecyl, lauryl, myristyl and stearyl chloride, bromide and iodide; and aryl(C₁-C₄)alkyl halides, for example benzyl chloride and phenethyl bromide. Both water- and oil-soluble compounds according to the invention can be prepared using such salts.

30 The above-mentioned pharmaceutical salts which are preferred include acetate, trifluoroacetate, besylate, citrate, fumarate, gluconate, hemisuccinate, hippurate, hydrochloride, hydrobromide, isethionate, mandelate, meglumine, nitrate, oleate, phosphonate, pivalate, sodium phosphate, 35 stearate, sulfate, sulfosalicylate, tartrate, thiomalate, tosylate and tromethamine, but this is not intended to represent a restriction.

5 The acid-addition salts of basic compounds of the formula I are prepared by bringing the free base form into contact with a sufficient amount of the desired acid, causing the formation of the salt in a conventional manner.

The free base can be regenerated by bringing the salt form into contact with a base and isolating the free base in a conventional manner. The free base forms differ in a certain respect from the corresponding salt forms thereof with respect to certain physical properties, such as solubility in polar solvents; for the purposes of the invention, however, the salts otherwise correspond to the respective free base forms thereof.

15 As mentioned, the pharmaceutically acceptable base-addition salts of the compounds of the formula I are formed with metals or amines, such as alkali metals and alkaline-earth metals or organic amines. Preferred metals are sodium, potassium, magnesium and calcium. Preferred organic amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methyl-D-glucamine and procaine.

20 The base-addition salts of acidic compounds according to the invention are prepared by bringing the free acid form into contact with a sufficient amount of the desired base, causing the formation of the salt in a conventional manner. The free acid can be regenerated by bringing the salt form into contact with an acid and isolating the free acid in a conventional manner. The free acid forms differ in a certain respect from the corresponding salt forms thereof with respect to certain physical properties, such as solubility in polar solvents; for the purposes of the invention, however, the salts otherwise correspond to the respective free acid forms thereof.

35 If a compound according to the invention contains more than one group which is capable of forming pharmaceutically acceptable salts of this type, the invention also encompasses multiple salts. Typical multiple salt forms include, for example, bitartrate, diacetate, difumarate, dimeglumine,

diphosphate, disodium and trihydrochloride, but this is not intended to represent a restriction.

5 With regard to that stated above, it can be seen that the expression "pharmaceutically acceptable salt" in the present connection is taken to mean an active ingredient which comprises a compound of the formula I in the form of one of its salts, in particular if this salt form imparts improved pharmacokinetic properties on the active ingredient compared with the free
10 form of the active ingredient or any other salt form of the active ingredient used earlier. The pharmaceutically acceptable salt form of the active ingredient can also provide this active ingredient for the first time with a desired pharmacokinetic property which it did not have earlier and can
15 even have a positive influence on the pharmacodynamics of this active ingredient with respect to its therapeutic efficacy in the body.

The invention furthermore relates to medicaments comprising at least one
20 compound of the formula I and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and/or adjuvants.

Pharmaceutical formulations can be administered in the form of dosage
25 units which comprise a predetermined amount of active ingredient per dosage unit. Such a unit can comprise, for example, 0.5 mg to 1 g, preferably 1 mg to 700 mg, particularly preferably 5 mg to 100 mg, of a compound according to the invention, depending on the condition treated, the
30 method of administration and the age, weight and condition of the patient, or pharmaceutical formulations can be administered in the form of dosage units which comprise a predetermined amount of active ingredient per dosage unit. Preferred dosage unit formulations are those which comprise a daily dose or part-dose, as indicated above, or a corresponding fraction
35 thereof of an active ingredient. Furthermore, pharmaceutical formulations

of this type can be prepared using a process which is generally known in the pharmaceutical art.

5 Pharmaceutical formulations can be adapted for administration via any desired suitable method, for example by oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) methods. Such formulations can be prepared using all
10 processes known in the pharmaceutical art by, for example, combining the active ingredient with the excipient(s) or adjuvant(s).

15 Pharmaceutical formulations adapted for oral administration can be administered as separate units, such as, for example, capsules or tablets; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or foam foods; or oil-in-water liquid emulsions or water-in-oil liquid emulsions.

20 Thus, for example, in the case of oral administration in the form of a tablet or capsule, the active-ingredient component can be combined with an oral, non-toxic and pharmaceutically acceptable inert excipient, such as, for example, ethanol, glycerol, water and the like. Powders are prepared by
25 comminuting the compound to a suitable fine size and mixing it with a pharmaceutical excipient comminuted in a similar manner, such as, for example, an edible carbohydrate, such as, for example, starch or mannitol. A flavour, preservative, dispersant and dye may likewise be present.

30 Capsules are produced by preparing a powder mixture as described above and filling shaped gelatine shells therewith. Glidants and lubricants, such as, for example, highly disperse silicic acid, talc, magnesium stearate, calcium stearate or polyethylene glycol in solid form, can be added to the
35 powder mixture before the filling operation. A disintegrant or solubiliser, such as, for example, agar-agar, calcium carbonate or sodium carbonate,

can likewise be added in order to improve the availability of the medication after the capsule has been taken.

5 In addition, if desired or necessary, suitable binders, lubricants and disintegrants as well as dyes can likewise be incorporated into the mixture. Suitable binders include starch, gelatine, natural sugars, such as, for example, glucose or beta-lactose, sweeteners made from maize, natural and synthetic rubber, such as, for example, acacia, tragacanth or sodium
10 alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like. The lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. The disintegrants include, without being restricted
15 thereto, starch, methylcellulose, agar, bentonite, xanthan gum and the like. The tablets are formulated by, for example, preparing a powder mixture, granulating or dry-pressing the mixture, adding a lubricant and a disintegrant and pressing the entire mixture to give tablets. A powder mixture is prepared by mixing the compound comminuted in a suitable manner with a
20 diluent or a base, as described above, and optionally with a binder, such as, for example, carboxymethylcellulose, an alginate, gelatine or polyvinylpyrrolidone, a dissolution retardant, such as, for example, paraffin, an absorption accelerator, such as, for example, a quaternary salt, and/or an
25 absorbant, such as, for example, bentonite, kaolin or dicalcium phosphate. The powder mixture can be granulated by wetting it with a binder, such as, for example, syrup, starch paste, acacia mucilage or solutions of cellulose or polymer materials and pressing it through a sieve. As an alternative to
30 granulation, the powder mixture can be run through a tableting machine, giving lumps of non-uniform shape, which are broken up to form granules. The granules can be lubricated by addition of stearic acid, a stearate salt, talc or mineral oil in order to prevent sticking to the tablet casting moulds. The lubricated mixture is then pressed to give tablets. The compounds
35 according to the invention can also be combined with a free-flowing inert excipient and then pressed directly to give tablets without carrying out the

granulation or dry-pressing steps. A transparent or opaque protective layer consisting of a shellac sealing layer, a layer of sugar or polymer material and a gloss layer of wax may be present. Dyes can be added to these coatings in order to be able to differentiate between different dosage units.

5

Oral liquids, such as, for example, solution, syrups and elixirs, can be prepared in the form of dosage units so that a given quantity comprises a pre-specified amount of the compound. Syrups can be prepared by dissolving the compound in an aqueous solution with a suitable flavour, while elixirs are prepared using a non-toxic alcoholic vehicle. Suspensions can be formulated by dispersion of the compound in a non-toxic vehicle. Solubilisers and emulsifiers, such as, for example, ethoxylated isostearyl alcohols and polyoxyethylene sorbitol ethers, preservatives, flavour additives, such as, for example, peppermint oil or natural sweeteners or saccharin, or other artificial sweeteners and the like, can likewise be added.

10

15

20

25

30

35

The dosage unit formulations for oral administration can, if desired, be encapsulated in microcapsules. The formulation can also be prepared in such a way that the release is extended or retarded, such as, for example, by coating or embedding of particulate material in polymers, wax and the like.

The compounds of the formula I and salts, solvates and physiologically functional derivatives thereof can also be administered in the form of liposome delivery systems, such as, for example, small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from various phospholipids, such as, for example, cholesterol, stearylamine or phosphatidylcholines.

The compounds of the formula I and the salts, solvates and physiologically functional derivatives thereof can also be delivered using monoclonal antibodies as individual carriers to which the compound molecules are cou-

pled. The compounds can also be coupled to soluble polymers as targeted
medicament carriers. Such polymers may encompass polyvinylpyrrolidone,
pyran copolymer, polyhydroxypropylmethacrylamidophenol, polyhydroxy-
ethylaspartamidophenol or polyethylene oxide polylysine, substituted by
5 palmitoyl radicals. The compounds may furthermore be coupled to a class
of biodegradable polymers which are suitable for achieving controlled
release of a medicament, for example polylactic acid, poly-epsilon-capro-
lactone, polyhydroxybutyric acid, polyorthoesters, polyacetals, polydihy-
10 droxypyrans, polycyanoacrylates and crosslinked or amphipathic block co-
polymers of hydrogels.

Pharmaceutical formulations adapted for transdermal administration can
15 be administered as independent plasters for extended, close contact with
the epidermis of the recipient. Thus, for example, the active ingredient can
be delivered from the plaster by iontophoresis, as described in general
terms in *Pharmaceutical Research*, 3(6), 318 (1986).

20 Pharmaceutical compounds adapted for topical administration can be for-
mulated as ointments, creams, suspensions, lotions, powders, solutions,
pastes, gels, sprays, aerosols or oils.

25 For the treatment of the eye or other external tissue, for example mouth
and skin, the formulations are preferably applied as topical ointment or
cream. In the case of formulation to give an ointment, the active ingredient
can be employed either with a paraffinic or a water-miscible cream base.
30 Alternatively, the active ingredient can be formulated to give a cream with
an oil-in-water cream base or a water-in-oil base.

Pharmaceutical formulations adapted for topical application to the eye
35 include eye drops, in which the active ingredient is dissolved or suspended
in a suitable carrier, in particular an aqueous solvent.

Pharmaceutical formulations adapted for topical application in the mouth encompass lozenges, pastilles and mouthwashes.

5 Pharmaceutical formulations adapted for rectal administration can be administered in the form of suppositories or enemas.

10 Pharmaceutical formulations adapted for nasal administration in which the carrier substance is a solid comprise a coarse powder having a particle size, for example, in the range 20-500 microns, which is administered in the manner in which snuff is taken, i.e. by rapid inhalation via the nasal passages from a container containing the powder held close to the nose. Suitable formulations for administration as nasal spray or nose drops with
15 a liquid as carrier substance encompass active-ingredient solutions in water or oil.

20 Pharmaceutical formulations adapted for administration by inhalation encompass finely particulate dusts or mists, which can be generated by various types of pressurised dispensers with aerosols, nebulisers or insufflators.

25 Pharmaceutical formulations adapted for vaginal administration can be administered as pessaries, tampons, creams, gels, pastes, foams or spray formulations.

30 Pharmaceutical formulations adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions comprising antioxidants, buffers, bacteriostatics and solutes, by means of which the formulation is rendered isotonic with the blood of the recipient to be treated; and aqueous and non-aqueous sterile suspensions, which may comprise suspension media and thickeners. The formulations can be administered in
35 single-dose or multidose containers, for example sealed ampoules and vials, and stored in freeze-dried (lyophilised) state, so that only the addition

of the sterile carrier liquid, for example water for injection purposes, immediately before use is necessary. Injection solutions and suspensions prepared in accordance with the recipe can be prepared from sterile powders, granules and tablets.

5

It goes without saying that, in addition to the above particularly mentioned constituents, the formulations may also comprise other agents usual in the art with respect to the particular type of formulation; thus, for example, formulations which are suitable for oral administration may comprise flavours.

10

A therapeutically effective amount of a compound of the formula I depends on a number of factors, including, for example, the age and weight of the animal, the precise condition that requires treatment, and its severity, the nature of the formulation and the method of administration, and is ultimately determined by the treating doctor or vet. However, an effective amount of a compound according to the invention for the treatment of neoplastic growth, for example colon or breast carcinoma, is generally in the range from 0.1 to 100 mg/kg of body weight of the recipient (mammal) per day and particularly typically in the range from 1 to 10 mg/kg of body weight per day. Thus, the actual amount per day for an adult mammal weighing 70 kg is usually between 70 and 700 mg, where this amount can be administered as a single dose per day or usually in a series of part-doses (such as, for example, two, three, four, five or six) per day, so that the total daily dose is the same. An effective amount of a salt or solvate or of a physiologically functional derivative thereof can be determined as the fraction of the effective amount of the compound according to the invention *per se*. It can be assumed that similar doses are suitable for the treatment of other conditions mentioned above.

15

20

25

30

35

The invention furthermore relates to medicaments comprising at least one compound of the formula I and/or pharmaceutically usable derivatives, sol-

vates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.

- 5 The invention also relates to a set (kit) consisting of separate packs of
- (a) an effective amount of a compound of the formula I and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and
 - 10 (b) an effective amount of a further medicament active ingredient.

The set comprises suitable containers, such as boxes, individual bottles, bags or ampoules. The set may, for example, comprise separate am-

15 poules, each containing an effective amount of a compound of the formula I and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and an effective amount of a further medicament active ingredient in dissolved or lyophilised form.

20

USE

The present compounds are suitable as pharmaceutical active ingredients for mammals, especially for humans, in the treatment and control of cancer diseases.

25

The present invention encompasses the use of the compounds of the formula I and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment or prevention of cancer.

30 Preferred carcinomas for the treatment originate from the group cerebral carcinoma, urogenital tract carcinoma, carcinoma of the lymphatic system, stomach carcinoma, laryngeal carcinoma and lung carcinoma bowel cancer. A further group of preferred forms of cancer are monocytic leukaemia,

35

lung adenocarcinoma, small-cell lung carcinomas, pancreatic cancer, glioblastomas and breast carcinoma.

5 Also encompassed is the use of the compounds of the formula I and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment and/or control of a tumour-induced disease in a mammal, in which to this method a therapeutically effective amount of a compound according to the invention is administered to a sick
10 mammal in need of such treatment. The therapeutic amount varies according to the particular disease and can be determined by the person skilled in the art without undue effort.

15 Particular preference is given to the use for the treatment of a disease, where the disease is a solid tumour.

The solid tumour is preferably selected from the group of tumours of the squamous epithelium, the bladder, the stomach, the kidneys, of head and
20 neck, the oesophagus, the cervix, the thyroid, the intestine, the liver, the brain, the prostate, the urogenital tract, the lymphatic system, the stomach, the larynx and/or the lung.

25 The solid tumour is furthermore preferably selected from the group lung adenocarcinoma, small-cell lung carcinomas, pancreatic cancer, glioblastomas, colon carcinoma and breast carcinoma.

30 Preference is furthermore given to the use for the treatment of a tumour of the blood and immune system, preferably for the treatment of a tumour selected from the group of acute myeloid leukaemia, chronic myeloid leukaemia, acute lymphatic leukaemia and/or chronic lymphatic leukaemia.

35 The invention furthermore relates to the use of the compounds according to the invention for the treatment of bone pathologies, where the bone

pathology originates from the group osteosarcoma, osteoarthritis and rickets.

5 The compounds of the formula I may also be administered at the same time as other well-known therapeutic agents that are selected for their particular usefulness against the condition that is being treated.

The present compounds are also suitable for combination with known anti-cancer agents. These known anti-cancer agents include the following:

10 oestrogen receptor modulators, androgen receptor modulators, retinoid receptor modulators, cytotoxic agents, antiproliferative agents, prenyl-protein transferase inhibitors, HMG-CoA reductase inhibitors, HIV protease inhibitors, reverse transcriptase inhibitors and further angiogenesis inhibitors. The present compounds are particularly suitable for administration at
15 the same time as radiotherapy.

"Oestrogen receptor modulators" refers to compounds which interfere with or inhibit the binding of oestrogen to the receptor, regardless of mechanism. Examples of oestrogen receptor modulators include, but are not limited to, tamoxifen, raloxifene, idoxifene, LY353381, LY 117081, toremifene, fulvestrant, 4-[7-(2,2-dimethyl-1-oxopropoxy-4-methyl-2-[4-[2-(1-piperidinyl)ethoxy]phenyl]-2H-1-benzopyran-3-yl]phenyl 2,2-dimethylpropanoate, 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and
25 SH646.

"Androgen receptor modulators" refers to compounds which interfere with or inhibit the binding of androgens to the receptor, regardless of mechanism. Examples of androgen receptor modulators include finasteride and
30 other 5 α -reductase inhibitors, nilutamide, flutamide, bicalutamide, liarozole and abiraterone acetate.

"Retinoid receptor modulators" refers to compounds which interfere with or inhibit the binding of retinoids to the receptor, regardless of mechanism. Examples of such retinoid receptor modulators include bexarotene, tretinoin,
35 13-cis-retinoic acid, 9-cis-retinoic acid, α -difluoromethylornithine,

ILX23-7553, trans-N-(4'-hydroxyphenyl)retinamide and N-4-carboxyphenyl-retinamide.

"Cytotoxic agents" refers to compounds which result in cell death primarily through direct action on the cellular function or inhibit or interfere with cell myosis, including alkylating agents, tumour necrosis factors, intercalators, microtubulin inhibitors and topoisomerase inhibitors.

Examples of cytotoxic agents include, but are not limited to, tirapazimine, sertenef, cachectin, ifosfamide, tasonermin, lonidamine, carboplatin, altret-amine, prednimustine, dibromodulcitol, ranimustine, fotemustine, nedaplatin, oxaliplatin, temozolomide, heptaplatin, estramustine, improsulfan tosylate, trofosfamide, nimustine, dibrospidium chloride, pumitepa, lobaplatin, satraplatin, profiromycin, cisplatin, irofulven, dexifosfamide, cis-aminedichloro(2-methylpyridine)platinum, benzylguanine, glufosfamide, GPX100, (trans,trans,trans)bis-mu-(hexane-1,6-diamine)-mu-[diamine-platinum(II)]bis[diamine(chloro)platinum(II)] tetrachloride, diarisidinylspermine, arsenic trioxide, 1-(11-dodecylamino-10-hydroxyundecyl)-3,7-dimethylxanthine, zorubicin, idarubicin, daunorubicin, bisantrene, mitoxantrone, pirarubicin, pinafide, valrubicin, amrubicin, antineoplaston, 3'-de-amino-3'-morpholino-13-deoxo-10-hydroxycarminomycin, annamycin, galarubicin, elinafide, MEN10755 and 4-demethoxy-3-deamino-3-aziridiny-4-methylsulfonyldaunorubicin (see WO 00/50032).

Examples of microtubulin inhibitors include paclitaxel, vindesine sulfate, 3',4'-didehydro-4'-deoxy-8'-norvincal leukoblastine, docetaxol, rhizoxin, dolastatin, mivobulin isethionate, auristatin, cemadotin, RPR109881, BMS184476, vinflunine, cryptophycin, 2,3,4,5,6-pentafluoro-N-(3-fluoro-4-methoxyphenyl)benzenesulfonamide, anhydrovinblastine, N,N-dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-prolyl-L-proline-t-butylamide, TDX258 and BMS188797.

Topoisomerase inhibitors are, for example, topotecan, hycaptamine, irinotecan, rubitecan, 6-ethoxypropionyl-3',4'-O-exobenzylidenechartreusin, 9-methoxy-N,N-dimethyl-5-nitropyrazolo[3,4,5-kl]acridine-2-(6H)propan-amine, 1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H,12H-

benzo[de]pyrano[3',4':b,7]indolizino[1,2b]quinoline-10,13(9H,15H)-dione, lurtotecan, 7-[2-(N-isopropylamino)ethyl]-(20S)camptothecin, BNP1350, BNPI1100, BN80915, BN80942, etoposide phosphate, teniposide, sobu-
 5 zoxane, 2'-dimethylamino-2'-deoxyetoposide, GL331, N-[2-(dimethyl-
 amino)ethyl]-9-hydroxy-5,6-dimethyl-6H-pyrido[4,3-b]carbazole-1-carbox-
 amide, asulacrine, (5a,5aB,8aa,9b)-9-[2-[N-[2-(dimethylamino)ethyl]-N-
 methylamino]ethyl]-5-[4-hydroxy-3,5-dimethoxyphenyl]-5,5a,6,8,8a,9-hexo-
 10 hydrofuro(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6-one, 2,3-(methylenedioxy)-
 5-methyl-7-hydroxy-8-methoxybenzo[c]phenanthridinium, 6,9-bis[(2-amino-
 ethyl)amino]benzo[g]isoquinoline-5,10-dione, 5-(3-aminopropylamino)-
 7,10-dihydroxy-2-(2-hydroxyethylaminomethyl)-6H-pyrazolo[4,5,1-de]-
 acridin-6-one, N-[1-[2(diethylamino)ethylamino]-7-methoxy-9-oxo-9H-thio-
 15 xanthen-4-ylmethyl]formamide, N-(2-(dimethylamino)ethyl)acridine-4-car-
 boxamide, 6-[[2-(dimethylamino)ethyl]amino]-3-hydroxy-7H-indeno[2,1-c]-
 quinolin-7-one and dimesna.

"Antiproliferative agents" include antisense RNA and DNA oligonucleotides
 20 such as G3139, ODN698, RVASKRAS, GEM231 and INX3001 and anti-
 metabolites such as enocitabine, carmofur, tegafur, pentostatin, doxifluri-
 dine, trimetrexate, fludarabine, capecitabine, galocitabine, cytarabine
 ocfosfate, fosteabine sodium hydrate, raltitrexed, paltitrexid, emittefur, tia-
 25 zofurin, decitabine, nolatrexed, pemetrexed, nelzarabine, 2'-deoxy-2'-
 methylidenecytidine, 2'-fluoromethylene-2'-deoxycytidine, N-[5-(2,3-
 dihydrobenzofuryl)sulfonyl]-N'-(3,4-dichlorophenyl)urea, N6-[4-deoxy-4-
 [N2-[2(E),4(E)-tetradecadienoyl]glycylamino]-L-glycero-B-L-mannohepto-
 pyranosyl]adenine, aplidine, ecteinascidin, troxacitabine, 4-[2-amino-4-oxo-
 30 4,6,7,8-tetrahydro-3H-pyrimidino[5,4-b]-1,4-thiazin-6-yl-(S)-ethyl]-2,5-thie-
 noyl-L-glutamic acid, aminopterin, 5-fluorouracil, alanosine, 11-acetyl-8-
 (carbamoxyloxymethyl)-4-formyl-6-methoxy-14-oxa-1,11-diazatetracyclo-
 (7.4.1.0.0)tetradeca-2,4,6-trien-9-ylacetic acid ester, swainsonine, lome-
 35 trexol, dexrazoxane, methioninase, 2'-cyano-2'-deoxy-N4-palmitoyl-1-B-D-
 arabinofuranosyl cytosine and 3-aminopyridine-2-carboxaldehyde thio-
 semicarbazone. "Antiproliferative agents" also include monoclonal anti-

bodies to growth factors other than those listed under "angiogenesis inhibitors", such as trastuzumab, and tumour suppressor genes, such as p53, which can be delivered via recombinant virus-mediated gene transfer (see US Patent No. 6,069,134, for example).

Evidence of the action of pharmacological inhibitors on the proliferation/vitality of tumour cells *in vitro*

1.0 Background

In the present experiment description, the inhibition of tumour cell proliferation/tumour cell vitality by active ingredients is described.

The cells are sown in a suitable cell density in microtitre plates (96-well format) and the test substances are added in the form of a concentration series. After four further days of cultivation in serum-containing medium, the tumour cell proliferation/tumour cell vitality can be determined by means of an Alamar Blue test system.

2.0 Experimental procedure

2.1 Cell culture

For example commercially available colon carcinoma cell lines, ovary cell lines, prostate cell lines or breast cell lines, etc.

The cells are cultivated in medium. At intervals of several days, the cells are detached from the culture dishes with the aid of trypsin solution and sown in suitable dilution in fresh medium. The cells are cultivated at 37° Celsius and 10% CO₂.

2.2. Sowing of the cells

A defined number of cells (for example 2000 cells) per culture/well in a volume of 180 µl of culture medium are sown in microtitre plates (96 well cell-culture plates) using a multichannel pipette. The cells are subsequently cultivated in a CO₂ incubator (37°C and 10% CO₂).

2.3. Addition of the test substances

5 The test substances are dissolved, for example, in DMSO and subsequently employed in corresponding concentration (if desired in a dilution series) in the cell culture medium. The dilution steps can be adapted depending on the efficiency of the active ingredients and the desired spread of the concentrations. Cell culture medium is added to the test
10 substances in corresponding concentrations. The addition of the test substances to the cells can take place on the same day as the sowing of the cells. To this end, in each case 20 µl of substance solution from the predilution plate are added to the cultures/wells. The cells are cultivated for a further 4 days at 37° Celsius and 10% CO₂.
15

2.4. Measurement of the colour reaction

20 In each case, 20 µl of Alamar Blue reagent are added per well, and the microtitre plates are incubated, for example, for a further seven hours in a CO₂ incubator (at 37°C and 10% CO₂). The plates are measured in a reader with a fluorescence filter at a wavelength of 540 nm. The plates can be shaken gently immediately before the measurement.
25

3. Evaluation

30 The absorbance value of the medium control (no cells and test substances used) is subtracted from all other absorbance values. The controls (cells without test substance) are set equal to 100 per cent, and all other absorbance values are set in relation thereto (for example in % of control):

Calculation:

35
$$\frac{100 * (\text{value with cells and test substance} - \text{value of medium control})}{(\text{value with cells} - \text{value of medium control})}$$

IC₅₀ values (50% inhibition) are determined with the aid of statistics programs, such as, for example, RS1.

IC₅₀ data for compounds according to the invention are shown in Table 1.

5

4.0 Test for the inhibition of PDK1

10 The experimental batches are carried out in a flashplate system with 384 wells/microtitration plate.

In each case, the PDK1 sample His₆-PDK1(Δ1-50)(3.4 nM), the PDK1 substrate biotin-bA-bA-KTFCGTPEYLAPEVRREPRILSEEEQEMFRDFDY-IADWC (400 nM), 4 μM ATP (with 0.2μCi of ³³P-ATP/well) and the test
15 substance in 50μl of conventional experimental solution per well are incubated at 30°C for 60 min. The test substances are employed in corresponding concentrations (if desired in a dilution series). The control is carried out without test substance. The reaction is stopped using standard
20 methods and washed. The activity of the kinase is measured via the incorporated radioactivity in top count. In order to determine the non-specific kinase reaction (blank value), the experimental batches are carried out in the presence of 100 nM staurosporin.

25

5.0 Evaluation

The radioactivity (decompositions per minute) of the blank value (no use of test substance in the presence of staurosporin) is subtracted from all other
30 radioactivity values. The controls (kinase activity without test substance) are set equal to 100 per cent and all other radioactivity values (after subtracting the blank value) are expressed set in relation thereto (for example in % of the control).

35

Calculation:

26474-1217

- 40 -

100* (value of the kinase activity with test substance - blank value)

(value of the control - blank value)

= % of the control

- 5 IC₅₀ values (50% inhibition) are determined with the aid of statistics programmes, such as, for example, RS1. IC₅₀ data of compounds according to the invention are indicated in Table 1.

10

	Material	Order No.	Manufacturer
	Microtitre plates for cell culture (Nunclon Surface 96-well plate)		167008 Nunc
15	DMEM	P04-03550	Pan Biotech
	PBS (10x) Dulbecco	14200-067	Gibco TM
	96-well plates (polypropylene)		267334 Nunc
20	AlamarBlue TM	BUF012B	Serotec
	FCS	1302	Pan Biotech GmbH
	Trypsin/EDTA solution 10x	L 2153	Biochrom AG
25	75cm ² culture bottles	353136	BD Falcon
	A2780	93112519	ECACC
	Colo205	CCL222	ATCC
	MCF7	HTB22	ATCC
30	PC3	CRL-1435	ATCC
	384-well flash plates	SMP410A001PK	Perkin Elmer
35	APCI-MS (atmospheric pressure chemical ionisation - mass spectrometry) (M+H) ⁺ .		

HPLC gradient system

Column:

ChromolithTM Performance RP-18e (Merck KGaA, Cat. 1.02129.0001)

5 Eluents:

Eluent A: 0.1 M aqueous NaH₂PO₄

Eluent B: acetonitrile + 10% of water

Flow rate: 4 ml/min

10 Gradient:

0 min 1% of B


1 min 1% of B

7 min 99% of B

15 8 min 99% of B

Example 1

20 The preparation of 4-butyl-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl-amine ("A1") is carried out analogously to the following scheme








1.1 526 mg (0.75 mmol) of bis(triphenylphosphine)palladium(II) chloride and 57.2 mg (0.30 mmol) of copper(I) iodide are added to a solution of 5.16 g (15.0 mmol) of tert-butyl 3-iodopyrrolo[2,3-b]pyridine-1-carboxylate in 100 ml of tetrahydrofuran. Carbon monoxide is passed into this solution in an autoclave apparatus. 1.85 g (22.5 mmol) of 1-hexine and 1.52 g (15 mmol) of triethylamine are then added. The reaction mixture is stirred in the autoclave apparatus for 48 hours under a pressure of 1 atm of carbon monoxide. The reaction mixture is washed with saturated sodium chloride solution, and the aqueous phase is extracted with dichloromethane. The combined organic phases are dried over sodium sulfate and evaporated. The residue is chromatographed on a silica-gel column with petroleum ether/ethyl acetate as eluent: tert-butyl 3-hept-2-ynoylpyrrolo[2,3-b]pyridine-1-carboxylate as colourless oil; ESI 327.

1.2 278 mg (2.0 mmol) of sodium carbonate are added to a solution of 314 mg (0.96 mmol) of tert-butyl 3-hept-2-inoylpyrrolo[2,3-b]pyridine-1-carboxylate and 130 mg (0.72 mmol) of guanidine carbonate in 2 ml of ethylene glycol monomethyl ether, and the mixture is heated at the boil for 24 hours. After cooling, the mixture is partitioned between water and ethyl acetate. The organic phase is dried over sodium sulfate, evaporated, and the residue is chromatographed using preparative HPLC, giving 4-butyl-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine ("A1") as colourless solid; ESI 269;

¹H NMR (DMSO-d₆) δ [ppm] 0.92 (t, J = 7.3 Hz, 3H), 1.35 (sextet, J = 7.3 Hz, 2H), 1.66 (quintet, J = 7.3 Hz, 2H), 2.49 (t, J = 7.3 Hz, 2H), 6.35 (s, 2H), 6.97 (s, 1H), 7.17 (dd, J₁ = 8.0 Hz, J₂ = 4.5 Hz, 1H), 8.27 (dd, J₁ = 4.5 Hz, J₂ = 1 Hz, 1H), 8.30 (d, J = 3 Hz, 1H), 8.90 (dd, J₁ = 4.5 Hz, J₂ = 8 Hz, J₂ = 1 Hz, 1H), 12.1 (bs, 1H).


The following compounds are obtained analogously

Compound No.	Name and/or structure	Analytical data
"A2"	4-Phenyl-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine	ESI 288
"A3"	4-Propyl-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine	ESI 254
"A4"	4-Methoxymethyl-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine 	
"A26"	3-[2-Amino-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]propan-1-ol 	ESI 270
"A27"	4-Methoxymethyl-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine 	ESI 256

5	"A28"	3-[2-Amino-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]propionic acid	ESI 284
10	"A29"	4-[2-Amino-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]butan-1-ol	ESI 284
15			
20	"A30"	4-[2-Amino-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]butyric acid	ESI 298
25			

Example 2

The preparation of 4-ethyl-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl-amine ("A5") is carried out analogously to the following scheme




2.1 5.6 g (42.0 mmol) of aluminium trichloride are added to a solution of 1.0 g (8.47 mmol) of pyrrolo[2,3-b]pyridine in 100 ml of dichloromethane, and the mixture is stirred at room temperature for 2 h. 52 ml (0.2 M, 10.09 mmol) of pent-2-ynoyl chloride dissolved in dichloromethane are then slowly added dropwise to the reaction solution. The mixture is left to stir at room temperature for a further 16 h. Saturated sodium hydrogen-carbonate solution is added to the reaction mixture until neutral, and the aluminium salt precipitate is filtered off with suction. The aqueous phase is separated off and extracted twice with dichloromethane. The combined organic phases are washed with saturated sodium chloride solution, dried over magnesium sulfate and evaporated. The residue is employed in the next reaction without further purification. 1-(1H-Pyrrolo[2,3-b]pyridin-3-yl)-pent-2-yn-1-one (74% purity) is obtained as colourless oil; ESI 199.

2.2 2.1 g (15.12 mmol) of potassium carbonate are added to a solution of 600 mg (3.03 mmol) of (1H-pyrrolo[2,3-b]pyridin-3-yl)pent-2-yn-1-one and 660 mg (3.66 mmol) of guanidine carbonate in 10 ml of ethylene glycol monomethyl ether, and the mixture is heated at the boil for 4 hours. After cooling, the mixture is partitioned between water and ethyl acetate. The organic phase is dried over sodium sulfate, evaporated, and the residue is

chromatographed using preparative HPLC, giving 4-ethyl-6-(1H-pyrrolo-
[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine ("A5") as colourless solid; ESI 240;
¹H NMR (DMSO-d₆) δ [ppm] 1.22 (t, J = 7.56 Hz, 3H), 2.50 (dq, J₁ =
4.0 Hz, J₂ = 1 Hz, 2H), 6.38 (s, 2H), 6.97 (s, 1H), 7.17 (dd, J₁ = 8.14 Hz,
J₂ = 4.68 Hz, 1H), 8.27 (dd, J₁ = 4.9 Hz, J₂ = 1.73 Hz, 1H), 8.32 (d, J =
2.89 Hz, 1H), 8.91 (dd, J₁ = 7.95 Hz, J₂ = 1.56 Hz, 1H), 12.12 (bs, 1H).


The following compounds are obtained analogously

Compound No.	Name and/or structure	Analytical data
"A6"	4-Pentyl-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine	ESI 282
"A8"	4-(4-Propylcyclohexyl)-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine 	ESI 336
"A9"	4-(4-Propylphenyl)-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine	ESI 330
"A10"	4-Methyl-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine	

5

"A31"

4-Methyl-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine




ESI 226

10

"A32"

4-(5-Bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-6-ethylpyrimidin-2-ylamine




ESI 319

15

"A33"

4-(3-Nitrophenyl)-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine




ESI 333

25

"A34"




4-(3-Aminophenyl)-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine



ESI 303

30

35

5	"A35"	4-Ethyl-6-(2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine 	ESI 254
10	"A36"	4-(4-Chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-6-ethylpyrimidin-2-ylamine 	ESI 274
20	"A37"	3-(2-Amino-6-ethylpyrimidin-4-yl)-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile 	ESI 265


30

35

Example 3

The preparation of 4-(1-benzyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-6-butylpyrimidin-2-ylamine ("A7") is carried out analogously to the following scheme

5



15

20

25

30

35

3.1 1.04 g (5.00 mmol) of N-benzyl-7-azaindole are dissolved in 25 ml of 1,2-dimethoxyethane under nitrogen and cooled to 0°C. 0.44 ml (5.00 mmol) of oxalyl chloride are then added dropwise at 0°C, and the reaction mixture is heated at the boil for 2 hours. 35 mg (0.05 mmol) of bis(triphenylphosphine)palladium(II) chloride, 10 mg (0.05 mmol) of copper(I) iodide, 0.59 ml (5.00 mmol) of 1-hexyne and 1.38 ml (10.0 mmol) of triethylamine are then added successively, and the reaction mixture is stirred at room temperature for 1 hour. The reaction mixture is diluted with saturated sodium chloride solution and extracted with 20 ml of dichloromethane. The combined organic phases are dried over sodium sulfate and evaporated. The residue is chromatographed on a silica-gel column with petroleum ether/ethyl acetate: 1-(1-benzyl-1H-pyrrolo[2,3-b]pyridin-3-yl)hept-2-yn-1-one as orange-yellow oil; ESI 317.

3.2 The cyclisation using guanidinium carbonate to give 4-(1-benzyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-6-butylpyrimidin-2-ylamine ("A7") (colourless crystals; ESI 358) is carried out analogously to Example 1.

5

The following compounds are obtained analogously



10

15

20

25


30

Compound No.	Name and/or structure	Analytical data
"A7a"	4-[1-(4-Methoxybenzyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-6-methoxymethylpyrimidin-2-ylamine 	ESI 376
"A38"	[2-Amino-6-(1-benzyl-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]methanol 	ESI 332

35


Example 4

The preparation of 4-hydroxymethyl-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)-pyrimidin-2-ylamine ("A11") is carried out analogously to the following scheme



The following compounds are obtained analogously

Compound No.	Name and/or structure	Analytical data
"A26"	3-[2-Amino-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]propan-1-ol 	ESI 270

"A29"	4-[2-Amino-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]butan-1-ol	ESI 284
		


Example 5

The preparation of

2-[2-amino-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-ylmethyl]isoindole-1,3-dione ("A12"),

4-aminomethyl-6-(pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine ("A15) and 4-(N,N-dimethylaminomethyl)-6-(pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine ("A18")

is carried out analogously to the following scheme




The following compounds are obtained analogously

25

30

35

Compound No.	Name and/or structure	Analytical data
"A13"	2-{3-[2-Amino-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]propyl}-isoindole-1,3-dione 	ESI 399

5





10

15

20

25


30

"A14"	2-{4-[2-Amino-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]butyl}-isoindole-1,3-dione 	ESI 413
"A16"	4-(3-Aminopropyl)-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine 	ESI 269
"A17"	4-(4-Aminobutyl)-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine 	ESI 283
"A19"		

35

Example 6

The preparation of 4-(pyrrolidin-1-ylpropyl)-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine ("A20") is carried out analogously to the following scheme


Example 7

The preparation of 4-(piperidin-4-ylmethyl)-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine ("A21") and 4-(1-methylpiperidin-4-ylmethyl)-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine ("A22") is carried out analogously to the following scheme

25

30

35



The preparation of the intermediate tert-butyl 4-prop-2-ynylpiperidine-1-carboxylate is carried out as described in WO00/59503 (page 215).

The following compounds are obtained analogously

Compound No.	Name and/or structure	Analytical data
"A23"		
"A24"		

5

10





15

20

25

30

35

"A25"		
"A39"	4-(3-Piperazin-1-ylpropyl)-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine 	ESI 338
"A40"	4-(3-Morpholin-4-ylpropyl)-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine 	ESI 339
"A41"	4-[3-(4-Methylpiperazin-1-yl)propyl]-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine 	ESI 352

Example 8

The preparation of 4-ethyl-6-{5-[1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl]-1H-pyrrolo[2,3-b]pyridin-3-yl}pyrimidin-2-ylamine is carried out in accordance with the following scheme

5

10


15

20

25

30

35



"A42"

8.1 A suspension of 1.00 g (5.0 mmol) of 5-bromo-7-azaindole, 2.00 g (9.1 mmol) of 1-methylpyrazole-4-boronic acid pinacol ester, 300 mg (0.26 mmol) of Pd[(PPh₃)₄ and 9 ml of Na₂CO₃ (addition as 2 M solution) in 12 ml of DMF is heated at 120°C under microwave conditions for 30 min. The reaction mixture is filtered, and the filtrate is evaporated. The residue is purified on a silica-gel column with dichloromethane/ methanol as eluent, giving 5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine as yellow solid, ESI 199

8.2 A solution of 1.125 g (4.4 mmol) of iodine in 16 ml of DMF is slowly added dropwise at RT to a suspension of 901 mg (4.4 mmol) of 5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine and 620 mg (11.1 mmol) of KOH in 12 ml of DMF. When the addition is complete, the mixture is stirred at RT for a further 30 min. The reaction mixture is subsequently poured into 300 ml of an ice-cold, saturated sodium sulfite solution. The yellow precipitate is filtered off with suction and washed with 10 ml of ice-cold water. The filter residue is dried, giving 3-iodo-5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine as beige crystals, ESI 325



8.3 0.3 ml (2.28 mmol) of triethylamine and 9 mg (0.07 mmol) of 4-(dimethylamino)pyridine are added to a solution of 238 mg (0.736 mmol) of 3-iodo-5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine in 2 ml of dichloromethane. A solution of 0.158 ml (0.783 mmol) of di-tert-butyl dicarbonate in 2.5 ml of dichloromethane is subsequently added dropwise to the reaction solution. The mixture is stirred at RT for 16 h. The reaction mixture is extracted twice with 5 ml of saturated sodium sulfite solution and once with water. The combined organic phases are dried over MgSO₄, the solid is separated off, and the solvent is removed in vacuo. The residue is separated on a silica-gel column with cyclohexane/ethyl acetate as eluent, giving tert-butyl 3-iodo-5-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,3-b]pyridine-1-carboxylate as brown gel-form substance, ESI 425

8.4 69 mg (0.10 mmol) of bis(triphenylphosphine)palladium(II) chloride and 19 mg (0.10 mmol) of copper(I) iodide are added to a solution of 417 mg (0.9 mmol) of tert-butyl 5-methylpyrazolo-3-iodopyrrolo[2,3-b]pyridine-1-carboxylate in 7.5 ml of tetrahydrofuran. Carbon monoxide is passed into this solution in an autoclave apparatus. 315 mg (0.145 mmol) of 2-pent-4-ynylisoindole-1,3-dione and 0.137 ml (0.925 mmol) of triethylamine are then added. The reaction mixture is stirred in the autoclave apparatus for 4 days under a pressure of 5 bar of carbon monoxide. The reaction mixture is evaporated in vacuo, and the residue is purified by preparative HPLC, giving 2-{6-[5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-6-oxohex-4-ynyl}isoindole-1,3-dione as yellow solid; ESI 438

8.5 0.92 ml (6.7 mmol) of triethylamine is added to a solution of 116 mg (0.265 mmol) of 2-{6-[5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-6-oxohex-4-ynyl}isoindole-1,3-dione and 70 mg (0.39 mmol) of guanidine carbonate in 4 ml of ethylene glycol monomethyl ether, and the mixture is heated at the boil for 6 hours. After cooling, the mixture is evaporated, and the residue is purified by preparative HPLC, giving 2-(3-{2-amino-6-[5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]pyrimidin-4-yl}propyl)isoindole-1,3-dione as brown solid; ESI 479, EMD 1183586.


8.6 0.003 ml (0.06 mmol) of hydrazinium hydroxide is added at RT to a solution of 29 mg (0.06 mmol) of 2-(3-{2-amino-6-[5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]pyrimidin-4-yl}propyl)isoindole-1,3-dione in 0.5 ml of methanol. The reaction solution is heated for 5 min at 60°C in the microwave. The reaction mixture is evaporated in vacuo, and the residue is purified by preparative HPLC, giving 4-(3-aminopropyl)-6-[5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]pyrimidin-2-ylamine as yellow solid, ESI 349

The following compounds are obtained analogously

Compound No.	Name and/or structure	Analytical data
"A43"	4-(3-Aminopropyl)-6-(5-furan-2-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine 	ESI 335
"A44"	4-(3-Aminopropyl)-6-[5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]pyrimidin-2-ylamine 	ESI 479

Example 9

The preparation of 4-ethyl-6-[5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]pyrimidin-2-ylamine is carried out in accordance with the following scheme



15

The preparation of EMD 1126600 is carried out analogously to Example 2.

20




25




30

A suspension of 50 mg (0.157 mmol) of 4-(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-6-ethylpyrimidin-2-ylamine, 56 mg (0.282 mmol) of methylpyrazole-4-boronic acid pinacol ester, 9 mg (0.008 mmol) of tetrakis(triphenylphosphine)palladium(0) and 0.45 ml of a 2M Na₂CO₃ solution (0.900 mmol) in 0.6 ml of DMF is heated for 30 min at 120°C in the microwave. The reaction mixture is filtered, the filter cake is washed with MeOH, and the filtrate is evaporated in vacuo. The residue is purified by preparative HPLC, giving 4-ethyl-6-[5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]pyrimidin-2-ylamine as a colourless solid, ESI 320.

35

The following compounds are obtained analogously

Compound No.	Name and/or structure	Analytical data
"A46"	4-Ethyl-6-(5-pyridin-3-yl-1H-pyrrolo-[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine 	ESI 317
"A47"	4-Ethyl-6-(5-pyridin-4-yl-1H-pyrrolo-[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine 	ESI 317
"A48"	4-[5-(6-Aminopyridin-3-yl)-1H-pyrrolo-[2,3-b]pyridin-3-yl]-6-ethylpyrimidin-2-ylamine 	ESI 332

5	"A49"	4-Ethyl-6-(5-furan-2-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine 	ESI 306
10	"A50"	3-Amino-5-[3-(2-amino-6-ethyl-pyrimidin-4-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]benzoic acid 	ESI 375
20	"A51"	4-[5-(3,5-Dimethylisoxazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-6-ethyl-pyrimidin-2-ylamine 	ESI 335

30

35

5

10




15

20

25

30

35

"A52"	4-Ethyl-6-(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine 	ESI 316
"A53"	4-[5-(6-Dimethylaminopyridin-3-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-6-ethylpyrimidin-2-ylamine 	ESI 360
"A54"	3-[3-(2-Amino-6-ethylpyrimidin-4-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]benzonitrile 	ESI 341

5

10




15

20

25

30

35

"A55"	4-Ethyl-6-{5-[1-(3-methoxypropyl)-1H-pyrazol-4-yl]-1H-pyrrolo[2,3-b]pyridin-3-yl}pyrimidin-2-ylamine 	ESI 378
"A56"	4-Ethyl-6-{5-[1-(2-methoxyethyl)-1H-pyrazol-4-yl]-1H-pyrrolo[2,3-b]pyridin-3-yl}pyrimidin-2-ylamine 	ESI 364
"A57"	4-Ethyl-6-[5-(6-fluoro-4-methylpyridin-3-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-pyrimidin-2-ylamine 	ESI 349

5

10




15

20

25

30

35

"A58"	N-Methyl-5-[3-(2-amino-6-ethyl-pyrimidin-4-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]pyridine-2-carboxamide 	ESI 374
"A59"	4-Ethyl-6-{5-[1-(3-methylbutyl)-1H-pyrazol-4-yl]-1H-pyrrolo[2,3-b]pyridin-3-yl}pyrimidin-2-ylamine 	ESI 376
"A60"	4-Ethyl-6-[5-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]pyrimidin-2-ylamine 	ESI 306

5

10




15




20

25

30

35

"A61"	4-Ethyl-6-[5-(2H-pyrazol-3-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]pyrimidin-2-ylamine 	ESI 306
"A62"	4-Ethyl-6-[5-(2-methyl-2H-pyrazol-3-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]pyrimidin-2-ylamine 	ESI 320
"A63"	4-Ethyl-6-[5-(1-isopropyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]pyrimidin-2-ylamine 	ESI 348

5	"A64"	4-Ethyl-6-[5-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]pyrimidin-2-ylamine	ESI 348
10			
15	"A65"	4-[3-(2-Amino-6-ethylpyrimidin-4-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-benzamide	ESI 359
20			
25	"A66"	4-Ethyl-6-[5-(1-isobutyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-pyrimidin-2-ylamine	ESI 362
30			


5	"A67"	4-(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-6-phenylpyrimidin-2-ylamine	ESI 367
10			

Table 1

15 Inhibition of the proliferation/ vitality of tumour cells/ inhibition of PDK1
IC₅₀ of compounds according to the invention

20	Compound No.	IC ₅₀ cells A2780 (ovary)
	"A1"	A
	"A2"	A
	"A3"	A
	"A5"	A
25	"A6"	B
	"A8"	B

30	Compound No.	IC ₅₀ PDK1
	"A16"	A
	"A32"	A
	"A42"	A
35	"A43"	A
	"A45"	A

5

"A48"	A
"A49"	A
"A56"	A
"A60"	A
"A66"	A

10

IC₅₀: 10 nM - 1 µM = A

1 µM - 10 µM = B

> 10 µM = C

The following examples relate to medicaments:

15

Example A: Injection vials

20

A solution of 100 g of an active ingredient of the formula I and 5 g of disodium hydrogenphosphate in 3 l of bidistilled water is adjusted to pH 6.5 using 2 N hydrochloric acid, sterile filtered, transferred into injection vials, lyophilised under sterile conditions and sealed under sterile conditions. Each injection vial contains 5 mg of active ingredient.

25

Example B: Suppositories

A mixture of 20 g of an active ingredient of the formula I with 100 g of soya lecithin and 1400 g of cocoa butter is melted, poured into moulds and allowed to cool. Each suppository contains 20 mg of active ingredient.

30

Example C: Solution

35

A solution is prepared from 1 g of an active ingredient of the formula I, 9.38 g of NaH₂PO₄ · 2 H₂O, 28.48 g of Na₂HPO₄ · 12 H₂O and 0.1 g of benzalkonium chloride in 940 ml of bidistilled water. The pH is adjusted to 6.8, and the solution is made up to 1 l and sterilised by irradiation. This solution can be used in the form of eye drops.

Example D: Ointment

500 mg of an active ingredient of the formula I are mixed with 99.5 g of VaselineTM under aseptic conditions.

5

Example E: Tablets

10

A mixture of 1 kg of active ingredient of the formula I, 4 kg of lactose, 1.2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is pressed in a conventional manner to give tablets in such a way that each tablet contains 10 mg of active ingredient.

Example F: Dragees

15

Tablets are pressed analogously to Example E and subsequently coated in a conventional manner with a coating of sucrose, potato starch, talc, tragacanth and dye.

Example G: Capsules

20

2 kg of active ingredient of the formula I are introduced into hard gelatine capsules in a conventional manner in such a way that each capsule contains 20 mg of the active ingredient.

Example H: Ampoules

25

A solution of 1 kg of active ingredient of the formula I in 60 l of bidistilled water is sterile filtered, transferred into ampoules, lyophilised under sterile conditions and sealed under sterile conditions. Each ampoule contains 10 mg of active ingredient.

30



35

26474-1217

- 73 -





CLAIMS:

1. A compound which is:

Compound No.	Name and/or structure
"A1"	4-Butyl-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl-amine
"A2"	4-Phenyl-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine
"A3"	4-Propyl-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine
"A4"	4-Methoxymethyl-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)-pyrimidin-2-ylamine 
"A5"	4-Ethyl-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl-amine
"A6"	4-Pentyl-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl-amine
"A7"	4-(1-Benzyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-6-butyl-pyrimidin-2-ylamine
"A7a"	4-[1-(4-Methoxybenzyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-6-methoxymethylpyrimidin-2-ylamine
"A8"	4-(4-Propylcyclohexyl)-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)-pyrimidin-2-ylamine 
"A9"	4-(4-Propylphenyl)-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)-pyrimidin-2-ylamine

26474-1217

- 74 -

"A11"	4-Hydroxymethyl-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)- pyrimidin-2-ylamine
"A12"	2-[2-Amino-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4- ylmethyl]isoindole-1,3-dione
"A13"	
"A14"	
"A15"	4-Aminomethyl-6-(pyrrolo[2,3-b]pyridin-3-yl)pyrimidin- 2-ylamine
"A16"	
"A17"	
"A18"	4-(N,N-Dimethylaminomethyl)-6-(pyrrolo[2,3-b]pyridin- 3-yl)pyrimidin-2-ylamine

26474-1217

-75-

5

10





15

20

25

30

35

"A19"	
"A20"	4-(Pyrrolidin-1-ylpropyl)-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine
"A21"	4-(Piperidin-4-ylmethyl)-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine
"A22"	4-(1-Methylpiperidin-4-ylmethyl)-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine
"A23"	
"A24"	
"A25"	
"A26"	3-[2-Amino-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]propan-1-ol
"A27"	4-Methoxymethyl-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine
"A28"	3-[2-Amino-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]propionic acid

26474-1217

- 76 -

5

10

15

20

25

30

35

"A29"	4-[2-Amino-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]butan-1-ol
"A30"	4-[2-Amino-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]butyric acid
"A31"	4-Methyl-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine
"A32"	4-(5-Bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-6-ethylpyrimidin-2-ylamine
"A33"	4-(3-Nitrophenyl)-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine
"A34"	4-(3-Aminophenyl)-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine
"A35"	4-Ethyl-6-(2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine
"A36"	4-(4-Chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-6-ethylpyrimidin-2-ylamine
"A37"	3-(2-Amino-6-ethylpyrimidin-4-yl)-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile
"A38"	[2-Amino-6-(1-benzyl-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]methanol
"A39"	4-(3-Piperazin-1-ylpropyl)-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine
"A40"	4-(3-Morpholin-4-ylpropyl)-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine
"A41"	4-[3-(4-Methylpiperazin-1-yl)propyl]-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine
"A42"	4-Ethyl-6-{5-[1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl]-1H-pyrrolo[2,3-b]pyridin-3-yl}pyrimidin-2-ylamine
"A43"	4-(3-Aminopropyl)-6-(5-furan-2-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-ylamine

26474-1217

- 77 -

5

10

15

20

25

30

35

"A44"	4-(3-Aminopropyl)-6-[5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]pyrimidin-2-ylamine
"A45"	4-Ethyl-6-[5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]pyrimidin-2-ylamine
"A46"	4-Ethyl-6-(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)-pyrimidin-2-ylamine
"A47"	4-Ethyl-6-(5-pyridin-4-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)-pyrimidin-2-ylamine
"A48"	4-[5-(6-Aminopyridin-3-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-6-ethylpyrimidin-2-ylamine
"A49"	4-Ethyl-6-(5-furan-2-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)-pyrimidin-2-ylamine
"A50"	3-Amino-5-[3-(2-amino-6-ethylpyrimidin-4-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]benzoic acid
"A51"	4-[5-(3,5-Dimethylisoxazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-6-ethylpyrimidin-2-ylamine
"A52"	4-Ethyl-6-(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-pyrimidin-2-ylamine
"A53"	4-[5-(6-Dimethylaminopyridin-3-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-6-ethylpyrimidin-2-ylamine
"A54"	3-[3-(2-Amino-6-ethylpyrimidin-4-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]benzonitrile
"A55"	4-Ethyl-6-{5-[1-(3-methoxypropyl)-1H-pyrazol-4-yl]-1H-pyrrolo[2,3-b]pyridin-3-yl}pyrimidin-2-ylamine
"A56"	4-Ethyl-6-{5-[1-(2-methoxyethyl)-1H-pyrazol-4-yl]-1H-pyrrolo[2,3-b]pyridin-3-yl}pyrimidin-2-ylamine
"A57"	4-Ethyl-6-[5-(6-fluoro-4-methylpyridin-3-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]pyrimidin-2-ylamine
"A58"	N-Methyl-5-[3-(2-amino-6-ethylpyrimidin-4-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]pyridine-2-carboxamide

26474-1217

- 78 -

"A59"	4-Ethyl-6-{5-[1-(3-methylbutyl)-1H-pyrazol-4-yl]-1H-pyrrolo[2,3-b]pyridin-3-yl}pyrimidin-2-ylamine
"A60"	4-Ethyl-6-[5-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]pyrimidin-2-ylamine
"A61"	4-Ethyl-6-[5-(2H-pyrazol-3-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]pyrimidin-2-ylamine
"A62"	4-Ethyl-6-[5-(2-methyl-2H-pyrazol-3-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]pyrimidin-2-ylamine
"A63"	4-Ethyl-6-[5-(1-isopropyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]pyrimidin-2-ylamine
"A64"	4-Ethyl-6-[5-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]pyrimidin-2-ylamine
"A65"	4-[3-(2-Amino-6-ethylpyrimidin-4-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]benzamide
"A66"	4-Ethyl-6-[5-(1-isobutyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]pyrimidin-2-ylamine
"A67"	4-(5-Bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-6-phenylpyrimidin-2-ylamine

or a pharmaceutically usable solvate, salt, tautomer or stereoisomer thereof, or a mixture thereof in any ratio.

2. A pharmaceutical composition comprising at least one compound according to Claim 1, or a pharmaceutically usable solvate, salt, tautomer or stereoisomer thereof, or a mixture thereof in any ratio, and an excipient and/or adjuvant.

26474-1217

- 79 -

3. The pharmaceutical composition according to Claim 2 for use in the treatment of a tumour, tumour growth, tumour metastasis and/or AIDS.

4. The pharmaceutical composition according to Claim 3, wherein the tumour originates from the squamous epithelium, the bladder, the stomach, the
5 kidneys, of head or neck, the oesophagus, the cervix, the thyroid, the intestine, the liver, the brain, the prostate, the urogenital tract, the lymphatic system, the larynx and/or the lung.

5. The pharmaceutical composition according to Claim 3, wherein the tumour originates from monocytic leukaemia, lung adenocarcinoma, a small-cell lung
10 carcinoma, pancreatic cancer, colon carcinoma, a glioblastoma and/or breast carcinoma.

6. The pharmaceutical composition according to Claim 3, wherein the tumour is a tumour of the blood or immune system.

7. The pharmaceutical composition according to Claim 3, wherein the
15 tumour originates from acute myeloid leukaemia, chronic myeloid leukaemia, acute lymphatic leukaemia and/or chronic lymphatic leukaemia.

8. The pharmaceutical composition according to Claim 2 for use in the treatment of a tumour, wherein the compound is for administration in combination with a compound which is 1) oestrogen receptor modulator, 2) androgen receptor
20 modulator, 3) retinoid receptor modulator, 4) cytotoxic agent, 5) antiproliferative agent, 6) prenyl-protein transferase inhibitor, 7) HMG-CoA reductase inhibitor, 8) HIV protease inhibitor, 9) reverse transcriptase inhibitor or 10) further angiogenesis inhibitors.

9. The pharmaceutical composition according to Claim 2, for use in the
25 treatment of a tumour, wherein the compound is for administration in combination with radiotherapy and a compound which is 1) oestrogen receptor modulator, 2) androgen receptor modulator, 3) retinoid receptor modulator, 4) cytotoxic agent,

26474-1217

- 80 -

5) antiproliferative agent, 6) prenyl-protein transferase inhibitor, 7) HMG-CoA reductase inhibitor, 8) HIV protease inhibitor, 9) reverse transcriptase inhibitor or 10) further angiogenesis inhibitors.

10. Use of a compound according to Claim 1, or a pharmaceutically usable solvate, salt, tautomer or stereoisomer thereof, or a mixture thereof in any ratio, for the preparation of a medicament for the treatment of a tumour, tumour growth, tumour metastasis and/or AIDS.

11. Use according to Claim 10, wherein the tumour originates from the squamous epithelium, the bladder, the stomach, the kidneys, of head or neck, the oesophagus, the cervix, the thyroid, the intestine, the liver, the brain, the prostate, the urogenital tract, the lymphatic system, the larynx and/or the lung.

12. Use according to Claim 10, wherein the tumour originates from monocytic leukaemia, lung adenocarcinoma, a small-cell lung carcinoma, pancreatic cancer, colon carcinoma, a glioblastoma and/or breast carcinoma.

13. Use according to Claim 10, wherein the tumour is a tumour of the blood or immune system.

14. Use according to Claim 10, wherein the tumour originates from acute myeloid leukaemia, chronic myeloid leukaemia, acute lymphatic leukaemia and/or chronic lymphatic leukaemia.

15. Use of a compound according to Claim 1, or a pharmaceutically usable solvate, salt, tautomer or stereoisomer thereof, or a mixture thereof in any ratio, for the preparation of a medicament for the treatment of a tumour, wherein the compound is for administration in combination with a compound which is 1) oestrogen receptor modulator, 2) androgen receptor modulator, 3) retinoid receptor modulator, 4) cytotoxic agent, 5) antiproliferative agent, 6) prenyl-protein transferase inhibitor, 7) HMG-CoA reductase inhibitor, 8) HIV protease inhibitor, 9) reverse transcriptase inhibitor or 10) further angiogenesis inhibitors.

26474-1217

- 81 -


16. Use of a compound according to Claim 1, or a pharmaceutically usable solvate, salt, tautomer or stereoisomer thereof, or a mixture thereof in any ratio, for the preparation of a medicament for the treatment of a tumour, wherein the compound is for administration in combination with radiotherapy and a compound
5 which is 1) oestrogen receptor modulator, 2) androgen receptor modulator, 3) retinoid receptor modulator, 4) cytotoxic agent, 5) antiproliferative agent, 6) prenyl-protein transferase inhibitor, 7) HMG-CoA reductase inhibitor, 8) HIV protease inhibitor, 9) reverse transcriptase inhibitor or 10) further angiogenesis inhibitors.
17. Use of a compound according to Claim 1, or a pharmaceutically usable
10 solvate, salt, tautomer or stereoisomer thereof, or a mixture thereof in any ratio, for the treatment of a tumour, tumour growth, tumour metastasis and/or AIDS.
18. Use according to Claim 17, wherein the tumour originates from the squamous epithelium, the bladder, the stomach, the kidneys, of head or neck, the oesophagus, the cervix, the thyroid, the intestine, the liver, the brain, the prostate, the
15 urogenital tract, the lymphatic system, the larynx and/or the lung.
19. Use according to Claim 17, wherein the tumour originates from monocytic leukaemia, lung adenocarcinoma, a small-cell lung carcinoma, pancreatic cancer, colon carcinoma, a glioblastoma and/or breast carcinoma.
20. Use according to Claim 17, wherein the tumour is a tumour of the blood
20 or immune system.
21. Use according to Claim 17, wherein the tumour originates from acute myeloid leukaemia, chronic myeloid leukaemia, acute lymphatic leukaemia and/or chronic lymphatic leukaemia.
22. Use of a compound according to Claim 1, or a pharmaceutically usable
25 solvate, salt, tautomer or stereoisomer thereof, or a mixture thereof in any ratio, for the treatment of a tumour, wherein the compound is for administration in combination with a compound which is 1) oestrogen receptor modulator, 2) androgen receptor

26474-1217

- 82 -

modulator, 3) retinoid receptor modulator, 4) cytotoxic agent, 5) antiproliferative agent, 6) prenyl-protein transferase inhibitor, 7) HMG-CoA reductase inhibitor, 8) HIV protease inhibitor, 9) reverse transcriptase inhibitor or 10) further angiogenesis inhibitors.

- 5 23. Use of a compound according to Claim 1, or a pharmaceutically usable solvate, salt, tautomer or stereoisomer thereof, or a mixture thereof in any ratio, for the treatment of a tumour, wherein the compound is for administration in combination with radiotherapy and a compound which is 1) oestrogen receptor modulator, 2) androgen receptor modulator, 3) retinoid receptor modulator, 4) cytotoxic agent, 5) antiproliferative agent, 6) prenyl-protein transferase inhibitor, 7) HMG-CoA reductase inhibitor, 8) HIV protease inhibitor, 9) reverse transcriptase inhibitor or 10) further angiogenesis inhibitors.
- 10



(II)